<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6631099</article-id><article-id pub-id-type="doi">10.3390/ph12020054</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-12-00054</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>TRP Channels and Migraine: Recent Developments and New Therapeutic Opportunities</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6316-430X</contrib-id><name><surname>Benemei</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-12-00054">1</xref></contrib><contrib contrib-type="author"><name><surname>Dussor</surname><given-names>Greg</given-names></name><xref ref-type="aff" rid="af2-pharmaceuticals-12-00054">2</xref><xref rid="c1-pharmaceuticals-12-00054" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceuticals-12-00054"><label>1</label>Headache Centre, Careggi University Hospital, Viale Pieraccini 18, 50139 Florence, Italy; <email>silvia.benemei@unifi.it</email></aff><aff id="af2-pharmaceuticals-12-00054"><label>2</label>School of Behavioral and Brain Sciences, Center for Advanced Pain Studies, The University of Texas at Dallas, Richardson, TX 75080, USA</aff><author-notes><corresp id="c1-pharmaceuticals-12-00054"><label>*</label>Correspondence: <email>gregory.dussor1@utdallas.edu</email>; Tel.: +1-972-883-2385</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>4</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2019</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>54</elocation-id><history><date date-type="received"><day>01</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>04</day><month>4</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Migraine is the second-most disabling disease worldwide, and the second most common neurological disorder. Attacks can last many hours or days, and consist of multiple symptoms including headache, nausea, vomiting, hypersensitivity to stimuli such as light and sound, and in some cases, an aura is present. Mechanisms contributing to migraine are still poorly understood. However, transient receptor potential (TRP) channels have been repeatedly linked to the disorder, including TRPV1, TRPV4, TRPM8, and TRPA1, based on their activation by pathological stimuli related to attacks, or their modulation by drugs/natural products known to be efficacious for migraine. This review will provide a brief overview of migraine, including current therapeutics and the link to calcitonin gene-related peptide (CGRP), a neuropeptide strongly implicated in migraine pathophysiology. Discussion will then focus on recent developments in preclinical and clinical studies that implicate TRP channels in migraine pathophysiology or in the efficacy of therapeutics. Given the use of onabotulinum toxin A (BoNTA) to treat chronic migraine, and its poorly understood mechanism, this review will also cover possible contributions of TRP channels to BoNTA efficacy. Discussion will conclude with remaining questions that require future work to more fully evaluate TRP channels as novel therapeutic targets for migraine.</p></abstract><kwd-group><kwd>ion channel</kwd><kwd>TRP</kwd><kwd>cortical spreading depression</kwd><kwd>meninges</kwd><kwd>dura mater</kwd><kwd>botulinum toxin A</kwd><kwd>reactive oxygen species</kwd><kwd>reactive nitrogen species</kwd><kwd>neurogenic inflammation</kwd><kwd>CGRP</kwd></kwd-group></article-meta></front><body><sec id="sec1-pharmaceuticals-12-00054"><title>1. Migraine: Epidemiology and Symptoms</title><p>Migraine is one of the most common diseases worldwide affecting over 14% of the adult population [<xref rid="B1-pharmaceuticals-12-00054" ref-type="bibr">1</xref>], with a gendered distribution in favor of females (2:1), and an increased prevalence in reproductive age for both genders [<xref rid="B2-pharmaceuticals-12-00054" ref-type="bibr">2</xref>]. Importantly, migraine is the most common severe primary headache, characterized by long-lasting (4&#x02013;72 hours) attacks of pain, accompanied by nausea, vomiting, and sensitivity to light and sound [<xref rid="B1-pharmaceuticals-12-00054" ref-type="bibr">1</xref>]. In current clinical practice, diagnosis of a migraine is made in accordance to the criteria of the International Headache Society (IHS) [<xref rid="B3-pharmaceuticals-12-00054" ref-type="bibr">3</xref>], which also allow the homogenous identification of the migraine phenotype worldwide for research purposes. According to the current version of the International Classification of Headache Disorders (ICHD-3) [<xref rid="B3-pharmaceuticals-12-00054" ref-type="bibr">3</xref>], the migraine can be with or without an aura (i.e., transient neurological symptoms, including visual or somatosensory or speech disturbances, that precede and/or accompany and/or follow the pain) and, in case of attacks for more than 15 days for 3 consecutive months, it can be classified as chronic. The most recent results from the Global Burden of Disease (GBD) study, promoted by the World Health Organization, reported migraine as the most disabling neurological disorder, and the second leading cause of years lived with disability (YLDs) worldwide [<xref rid="B4-pharmaceuticals-12-00054" ref-type="bibr">4</xref>]. The high disability, combined with the high prevalence, causes a significant socio-economic burden. In the European Union, where migraine is estimated to affect 75 million patients, each year it costs ~111 billion &#x020ac;, of which 93% is given for absence from work and reduced productivity [<xref rid="B5-pharmaceuticals-12-00054" ref-type="bibr">5</xref>].</p></sec><sec id="sec2-pharmaceuticals-12-00054"><title>2. Migraine: Therapeutics and Pathophysiology</title><p>Therapeutic options for the treatment of migraine include drugs for both the attacks, aimed to abort ongoing pain and reduce migraine-related symptoms, and prophylaxis. Acute treatment of attacks is recommended in any episode in any patient, while prophylaxis is recommended in the case of patients suffering more than four attacks/days of headache per month. Currently available and recommended drugs for the acute treatment of attacks encompass analgesics (i.e., paracetamol), non-steroidal anti-inflammatory drugs (NSAIDs), triptans, antiemetics and combinations of analgesics; while ergot derivatives and opioids maintain only a marginal role in therapy. Preventive treatments are to a large extent borrowed from other therapeutic areas, including antihypertensive agents (e.g., angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers, beta blockers), antiepileptic drugs (e.g., topiramate, sodium valproate, gabapentin), tricyclic antidepressants (e.g., amitriptyline, nortriptyline), but there are also some drugs used only with migraine prevention objectives, such as flunarizine and pizotifene [<xref rid="B1-pharmaceuticals-12-00054" ref-type="bibr">1</xref>]. Importantly, recent clinical evidence has supported the inclusion of onabotulinum toxin A (BoNTA) among the recommended drugs for migraine prevention, but only for chronic patients [<xref rid="B6-pharmaceuticals-12-00054" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-12-00054" ref-type="bibr">7</xref>].</p><p>Mechanisms contributing to migraine are multifactorial, complex, and not yet completely clarified [<xref rid="B8-pharmaceuticals-12-00054" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-12-00054" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-12-00054" ref-type="bibr">10</xref>]. Notwithstanding the huge number of studies, including genome-wide association studies (GWAS), the role of genetic factors still remains poorly defined [<xref rid="B11-pharmaceuticals-12-00054" ref-type="bibr">11</xref>], with the exception of hemiplegic migraine, which has, for a good portion of cases, a classical mendelian transmission. After years of open debate that has counter posed the neuronal and the vascular theory, migraine is now considered a neurovascular disorder, with a primary role of the trigeminovascular system in the mechanism of pain [<xref rid="B12-pharmaceuticals-12-00054" ref-type="bibr">12</xref>]. Following its first proposal, the neurovascular hypothesis has been corroborated by preclinical and clinical data showing the involvement of neurogenic inflammation and, in particular, of the neuropeptide calcitonin gene related peptide (CGRP) [<xref rid="B12-pharmaceuticals-12-00054" ref-type="bibr">12</xref>].</p><p>Neurogenic inflammation is a sterile inflammation mediated by the activation of trigeminal perivascular fibers that release neuropeptides, such as substance P and&#x02014;most importantly in humans&#x02014;CGRP, that induce increased blood flow and edema [<xref rid="B12-pharmaceuticals-12-00054" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-12-00054" ref-type="bibr">13</xref>]. Importantly, it has been shown in preclinical models that the activation of meningeal nociceptors could stimulate the trigeminal ganglia [<xref rid="B14-pharmaceuticals-12-00054" ref-type="bibr">14</xref>], thus in turn perpetuating the release of vasoactive peptides, including CGRP.</p></sec><sec id="sec3-pharmaceuticals-12-00054"><title>3. CGRP and Migraine</title><p>CGRP, a neuropeptide produced from alternative splicing of the calcitonin gene, acts as a relevant signaling peptide in mammalian biology, with a crucial role in both physiological and pathological conditions. In particular, because of its potent action as a vasodilator, it is involved in the physiological regulation of vascular tone and blood pressure, and some evidence has been collected for a role in cardiovascular diseases and extra-cardiovascular conditions [<xref rid="B15-pharmaceuticals-12-00054" ref-type="bibr">15</xref>].</p><p>There are two CGRP forms differently expressed in humans, alpha-CGRP (primary sensory neurons of the dorsal root ganglia, vagal ganglia and trigeminal system) and beta-CGRP (intrinsic enteric neurons) [<xref rid="B16-pharmaceuticals-12-00054" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-12-00054" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-12-00054" ref-type="bibr">18</xref>]. According to the expression pattern, alpha-CGRP is primarily involved in migraine pathogenesis. CGRP acts via a G protein-coupled receptor constituted by the calcitonin receptor-like receptor (CLR), the receptor activity-modifying protein 1 (RAMP1) and a receptor component protein (RCP), all of which are necessary to form the functional CGRP receptor [<xref rid="B12-pharmaceuticals-12-00054" ref-type="bibr">12</xref>]. In the last decades, both preclinical and clinical evidence has accumulated supporting a role of CGRP in migraine mechanisms. First, CGRP levels are increased during a migraine attack [<xref rid="B19-pharmaceuticals-12-00054" ref-type="bibr">19</xref>] and in chronic migraine patients also in the pain-free interval [<xref rid="B20-pharmaceuticals-12-00054" ref-type="bibr">20</xref>], returning to normal levels after triptan administration associated with headache resolution [<xref rid="B21-pharmaceuticals-12-00054" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-12-00054" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-12-00054" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-12-00054" ref-type="bibr">24</xref>]. Second, intravenous infusion of CGRP can induce migraine-like attacks in migraine patients [<xref rid="B25-pharmaceuticals-12-00054" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-12-00054" ref-type="bibr">26</xref>]. Third, animal data suggest that CGRP can induce the generation of light intolerance, which may be considered a parallel of human photophobia, a phenomenon typically reported during migraine attack [<xref rid="B27-pharmaceuticals-12-00054" ref-type="bibr">27</xref>]. According to the abovementioned evidence, CGRP is considered a relevant target for migraine, and many efforts have been made to show that CGRP antagonism, by small molecules antagonists of CGRP receptor [<xref rid="B28-pharmaceuticals-12-00054" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-12-00054" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceuticals-12-00054" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-12-00054" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-12-00054" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceuticals-12-00054" ref-type="bibr">33</xref>], an anti-CGRP receptor antibody [<xref rid="B34-pharmaceuticals-12-00054" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceuticals-12-00054" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceuticals-12-00054" ref-type="bibr">36</xref>] and anti-CGRP peptide antibodies [<xref rid="B37-pharmaceuticals-12-00054" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-12-00054" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceuticals-12-00054" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceuticals-12-00054" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-12-00054" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceuticals-12-00054" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-12-00054" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceuticals-12-00054" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceuticals-12-00054" ref-type="bibr">45</xref>] are all efficacious for the treatment or prevention of migraine.</p></sec><sec id="sec4-pharmaceuticals-12-00054"><title>4. Recent Findings on TRP Channels and Migraine Pain</title><p>While the mechanisms leading to the pain phase of migraine are unclear, the most likely explanation is that activation of nociceptors innervating the cranial meninges (and possibly the cerebral/meningeal vasculature) is responsible for the generation of headache [<xref rid="B12-pharmaceuticals-12-00054" ref-type="bibr">12</xref>,<xref rid="B46-pharmaceuticals-12-00054" ref-type="bibr">46</xref>]. Dilation of meningeal vessels on the headache side during migraine attacks triggered by cilostazol has recently been found, a finding that the authors suggest is an indicator of meningeal nociceptor activation [<xref rid="B47-pharmaceuticals-12-00054" ref-type="bibr">47</xref>], but this can only be taken as correlation and not causation of headache at this point. However, little information currently exists as to what specific mechanisms cause the activation of nociceptors in the meninges and/or near vessels. This includes a lack of knowledge of the extracellular events within the tissues themselves that occur during migraine attacks and the receptors expressed on nociceptors that respond to these events.</p><p>Transient receptor potential (TRP) channels are a family of cation channels expressed primarily on the cell membrane that cluster into six families including TRPA, TRPC, TRPM, TRPP, TRPL, and TRPV [<xref rid="B48-pharmaceuticals-12-00054" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceuticals-12-00054" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceuticals-12-00054" ref-type="bibr">50</xref>]. These channels are likely to contribute to a number of different physiological processes ranging from thermosensation and pain to regulation of Ca<sup>2+</sup> levels in the endoplasmic reticulum. Of relevance to the current discussion, they have been repeatedly hypothesized to contribute to migraine, specifically as an activation mechanism of meningeal nociceptors. Reasons for the interest in a TRP channel contribution to migraine are largely due to their expression on meningeal nociceptors and their responsiveness to a variety of endogenous and exogenous stimuli that may be of relevance to migraine attacks (<xref ref-type="fig" rid="pharmaceuticals-12-00054-f001">Figure 1</xref>). Further, activation of TRP channels is well-known to promote the release of CGRP from sensory nerve endings, and they have been used extensively as probes for the function of CGRP in various processes [<xref rid="B15-pharmaceuticals-12-00054" ref-type="bibr">15</xref>,<xref rid="B51-pharmaceuticals-12-00054" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceuticals-12-00054" ref-type="bibr">52</xref>]. Given the role of CGRP in migraine described above, and the as yet unclear mechanism by which CGRP is released during migraine, TRP channels remain a focus of interest for their potential contribution to attacks. A number of reviews on the topic of TRP channels and migraine have been published in recent years documenting the evidence that exists supporting their role in meningeal nociceptor activation [<xref rid="B51-pharmaceuticals-12-00054" ref-type="bibr">51</xref>,<xref rid="B53-pharmaceuticals-12-00054" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceuticals-12-00054" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceuticals-12-00054" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceuticals-12-00054" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceuticals-12-00054" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceuticals-12-00054" ref-type="bibr">58</xref>], so only brief discussion of older work will be given here, while the focus will be on newer TRP channel migraine studies.</p><sec id="sec4dot1-pharmaceuticals-12-00054"><title>4.1. TRPV1</title><p>Based primarily on preclinical animal studies, it is clear that sensory neurons that innervate the meninges express TRPA1, TRPV1, TRPV4, and TRPM8 [<xref rid="B51-pharmaceuticals-12-00054" ref-type="bibr">51</xref>,<xref rid="B53-pharmaceuticals-12-00054" ref-type="bibr">53</xref>]. This is not likely to be an all-inclusive list as other TRP channels have not yet been extensively studied in this context. One of the first TRP channels to be investigated was TRPV1, which is activated by capsaicin and also sensitive to endocannabinoids, endovanilloids, lipoxygenase metabolites, nerve-growth factor, and prostaglandins, among other factors many of which may be relevant for migraine [<xref rid="B48-pharmaceuticals-12-00054" ref-type="bibr">48</xref>]. TRPV1 was hypothesized to be present on meningeal sensory fibers based on early studies with capsaicin application to the meninges (e.g. [<xref rid="B59-pharmaceuticals-12-00054" ref-type="bibr">59</xref>]). It was later directly demonstrated on these neurons using immunohistochemistry [<xref rid="B60-pharmaceuticals-12-00054" ref-type="bibr">60</xref>] and recently shown on nerve fibers in the arterial wall of scalp vessels from chronic migraine patients, where channel expression was higher compared to healthy controls [<xref rid="B61-pharmaceuticals-12-00054" ref-type="bibr">61</xref>]. Mechanisms leading to increased TRPV1 expression in chronic migraine patients are unclear, but preclinical studies using repeated 30-day administration of eletriptan or indomethacin found increased TRPV1 (and TRPA1) in the trigeminal ganglia, so migraine itself may upregulate the channel and/or migraine therapeutics may also have this potential [<xref rid="B62-pharmaceuticals-12-00054" ref-type="bibr">62</xref>].</p><p>There have been numerous studies using capsaicin and TRPV1 antagonists to probe meningeal afferent and vascular function and these studies suggest a role for the channel in headache mechanisms [<xref rid="B51-pharmaceuticals-12-00054" ref-type="bibr">51</xref>]. Recent studies using this approach have found differential capsaicin-induced meningeal blood flow changes in the presence of diet-induced obesity [<xref rid="B63-pharmaceuticals-12-00054" ref-type="bibr">63</xref>] in mice and suggest a role for TRPV1 signaling in the increased prevalence of migraine with obesity (consistent with the increase in capsaicin-induced nociception and photophobia with obesity [<xref rid="B64-pharmaceuticals-12-00054" ref-type="bibr">64</xref>]; a similar finding was also seen with TRPA1 [<xref rid="B65-pharmaceuticals-12-00054" ref-type="bibr">65</xref>]). Capsaicin stimulation of facial skin in human has also been used as a surrogate to study trigeminal-mediated dural vasodilation [<xref rid="B66-pharmaceuticals-12-00054" ref-type="bibr">66</xref>]. Using this assay, increased dermal blood flow was seen in female (but not male) migraine patients compared to controls, suggesting that changes occur in TRPV1 fiber neurovascular responses in migraine [<xref rid="B67-pharmaceuticals-12-00054" ref-type="bibr">67</xref>]; similar changes in migraine patients in capsaicin-induced dermal blood flow were also recently published [<xref rid="B68-pharmaceuticals-12-00054" ref-type="bibr">68</xref>].</p><p>The above studies still do not address the mechanisms by which TRPV1 may be activated in the meninges during migraine attacks, they only show that the function of the channel or TRPV1-expressing fibers are altered with migraine-like conditions. In one of the few recent studies addressing a potential mechanism for TRPV1 activation, the authors used two-photon in vivo imaging of anesthetized mouse to examine macrophage morphology and dendritic cell motility in the meninges in relation to cortical-spreading depression (CSD), which is thought to be the underlying basis of migraine aura and has been shown to activate meningeal nociceptors [<xref rid="B69-pharmaceuticals-12-00054" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceuticals-12-00054" ref-type="bibr">70</xref>]. In time with CSD, meningeal macrophages changed to an active-like shape and migration of dendritic cells stopped [<xref rid="B71-pharmaceuticals-12-00054" ref-type="bibr">71</xref>]. The functional consequences of either of these events is not clear, but both cell types were found near TRPV1-expressing neurons, suggesting that CSD may alter meningeal immune cell function, which subsequently signal to this population of nociceptors. These studies are consistent with earlier findings on meningeal immune cells where CSD caused degranulation of mast cells [<xref rid="B72-pharmaceuticals-12-00054" ref-type="bibr">72</xref>], and together further implicate [<xref rid="B73-pharmaceuticals-12-00054" ref-type="bibr">73</xref>] changes in meningeal immune cell function during migraine as one mechanism of activation of dural nociceptors. Ultimately, while there may be a role for this channel in meningeal afferent signaling and in headache, the TRPV1 antagonist SB-705498 failed in a clinical migraine study [<xref rid="B74-pharmaceuticals-12-00054" ref-type="bibr">74</xref>]. This does not exclude a possibility for TRPV1 in migraine pathology, but it casts serious doubt on selective TRPV1 antagonism as a therapeutic approach and suggests that activation of TRPV1 alone is not sufficient to generate the headache phase of migraine.</p></sec><sec id="sec4dot2-pharmaceuticals-12-00054"><title>4.2. TRPV4</title><p>The TRPV4 channel responds to a number of stimuli including changes in osmolarity (cell swelling) and the resulting mechanical forces imposed on the cell membrane [<xref rid="B75-pharmaceuticals-12-00054" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceuticals-12-00054" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceuticals-12-00054" ref-type="bibr">77</xref>], suggesting that this channel serves as part of a mechanosensory complex. It is thus interesting in the context of migraine as headache is known to be influenced by changes in intracranial pressure e.g. when coughing, sneezing, standing or sitting, or exercising [<xref rid="B78-pharmaceuticals-12-00054" ref-type="bibr">78</xref>]. TRPV4 is also expressed in the vasculature where its activity likely contributes to vascular permeability, among other functions [<xref rid="B79-pharmaceuticals-12-00054" ref-type="bibr">79</xref>]. Expression of TRPV4 on meningeal nociceptors was shown using application of channel activators to retrogradely-labeled trigeminal neurons in vitro, which produced currents consistent with TRPV4, and activation of this channel in the dura caused headache behavioral responses in rats [<xref rid="B80-pharmaceuticals-12-00054" ref-type="bibr">80</xref>]. Unfortunately, little work has been done directly examining TRPV4 and headache since this publication. TRPV4 function in sensory neurons is known to be modulated downstream of the protease-activated receptor 2 (PAR2) [<xref rid="B81-pharmaceuticals-12-00054" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceuticals-12-00054" ref-type="bibr">82</xref>,<xref rid="B83-pharmaceuticals-12-00054" ref-type="bibr">83</xref>] and PAR2 activation sensitizes meningeal nociceptors to mechanical stimulation [<xref rid="B84-pharmaceuticals-12-00054" ref-type="bibr">84</xref>]. Until recently, preclinical behavioral studies had not been conducted with PAR2 activation in the meninges. Using more selective PAR2 agonists than those in prior studies, it was found that dural PAR2 activation causes headache behaviors in mice that were blocked by a selective PAR2 antagonist and absent in PAR2 knockout mice [<xref rid="B85-pharmaceuticals-12-00054" ref-type="bibr">85</xref>]. These studies provide further <italic>indirect</italic> evidence that TRPV4 activity on meningeal nociceptors may contribute to headache, but it remains unclear whether TRPV4 plays a direct role in the ability of meningeal afferents to detect pressure changes. More studies are needed to better explore the potential role for this channel in migraine.</p></sec><sec id="sec4dot3-pharmaceuticals-12-00054"><title>4.3. TRPM8</title><p>Non-noxious cool temperature, natural products such as menthol, and synthetic compounds such as icilin are all known to activate TRPM8; this channel has been implicated in pain signaling in numerous prior studies [<xref rid="B86-pharmaceuticals-12-00054" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceuticals-12-00054" ref-type="bibr">87</xref>]. It has also been the subject of much interest in the migraine community, initially based on the repeated identification of single-nucleotide polymorphisms (SNPs) and variants in the channel gene in numerous GWAS [<xref rid="B53-pharmaceuticals-12-00054" ref-type="bibr">53</xref>,<xref rid="B87-pharmaceuticals-12-00054" ref-type="bibr">87</xref>], most recently in a Taiwanese population study [<xref rid="B88-pharmaceuticals-12-00054" ref-type="bibr">88</xref>]. TRPM8 is found on trigeminal nerve fibers innervating the dura and appears to undergo developmental regulation where decreased expression occurs with age in mice such that relatively few neurons express TRPM8 in adult [<xref rid="B89-pharmaceuticals-12-00054" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceuticals-12-00054" ref-type="bibr">90</xref>]. There have been conflicting reports as to what behavioral consequences are present when TRPM8 is activated in the meninges since studies have shown both increases [<xref rid="B91-pharmaceuticals-12-00054" ref-type="bibr">91</xref>] and decreases [<xref rid="B89-pharmaceuticals-12-00054" ref-type="bibr">89</xref>] in headache behavior in rodents following dural application of agonists. Ultimately, the context of when channel activation occurs may be relevant; if TRPM8 is activated alone it may cause headache as in the case of &#x0201c;ice cream headaches&#x0201d; while if it is activated along with ongoing inflammation, it may serve as an analgesic mechanism as is the case for topical menthol [<xref rid="B53-pharmaceuticals-12-00054" ref-type="bibr">53</xref>]. Consistent with this idea is a recent publication demonstrating that when TRPM8 is activated in the presence of an ongoing inflammatory state induced by a cocktail of inflammatory mediators, the effect was a reduction in headache-related behavior [<xref rid="B92-pharmaceuticals-12-00054" ref-type="bibr">92</xref>]. These authors also found increased overlap of TRPV1 and TRPM8 in the same trigeminal neurons innervating the dura in the presence of meningeal inflammation, suggesting changes in channel expression occur under these conditions. Interestingly, while TRPV1 and TRPM8 are not co-expressed in dorsal root ganglia [<xref rid="B93-pharmaceuticals-12-00054" ref-type="bibr">93</xref>], co-expression has been found in trigeminal neurons [<xref rid="B94-pharmaceuticals-12-00054" ref-type="bibr">94</xref>], although as mentioned above, its expression is subject to developmental regulation. Using a PC12 cell-based assay, they also found that TRPM8 activation could inhibit function of TRPV1 when both channels were expressed by the cells. Together, these new studies support the context-specific role of TRPM8 in migraine. The context of channel activation during native migraine attacks is not yet clear, so it remains unknown what role the channel plays. This latter point is particularly relevant for drug discovery as it is not known whether an agonist or antagonist would show efficacy for migraine. Nonetheless, Amgen recently published preclinical pharmacology and human safety data on a novel TRPM8 antagonist proposed to be tested for migraine [<xref rid="B95-pharmaceuticals-12-00054" ref-type="bibr">95</xref>].</p><p>One of the more intriguing studies related to TRPM8 and migraine in recent years was the finding that the TRPM8 SNP rs10166942 (either C or T at chr2:234835093), which has been identified in GWAS of migraine populations [<xref rid="B53-pharmaceuticals-12-00054" ref-type="bibr">53</xref>], is differentially expressed across the Earth depending on latitude [<xref rid="B96-pharmaceuticals-12-00054" ref-type="bibr">96</xref>]. It was previously reported that humans who carry the T;T allele have a higher risk of migraine than those carrying the rarer versions C;C or C;T [<xref rid="B5-pharmaceuticals-12-00054" ref-type="bibr">5</xref>,<xref rid="B97-pharmaceuticals-12-00054" ref-type="bibr">97</xref>]. The authors of this new study found that the frequency of T-allele expression was only 5% in populations native to Nigeria while it was 88% in those native to Finland, with South and East Asian populations between these extremes at 48% and 36%, respectively. Thus, T-allele frequency seems to be predicted by a latitudinal cline, suggesting that human migraine to the colder climates of Northern Europe introduced positive-selection pressure on TRPM8. Additionally, this further suggests that the variants in the channel may respond differentially to temperature (possibly with lower activity in colder climates which would facilitate adaptation to those environments), although it is not yet known what these variants do to channel function/expression. Nonetheless, the latitudinal cline of T-allele expression (higher in colder climates, lower in warmer climates) matches with the epidemiology of migraine which shows higher prevalence in Europe, lower prevalence in Africa, and intermediate prevalence in Asia (discussed in [<xref rid="B96-pharmaceuticals-12-00054" ref-type="bibr">96</xref>]). Better understanding of what the SNPs at rs10166942 do to the expression/function of TRPM8 will likely provide much insight into how the channel may be contributing to migraine, whether by greater or lesser activation during attacks.</p></sec><sec id="sec4dot4-pharmaceuticals-12-00054"><title>4.4. TRPA1</title><p>The TRPA1 channel has probably received the most attention in preclinical headache/migraine studies as it is activated by an extensive list of endogenous and exogenous stimuli that may have relevance for migraine. These include reactive oxygen and nitrogen species, reactive prostaglandins, and many environmental irritants such as chlorine, formaldehyde, cigarette smoke, and acrolein [<xref rid="B51-pharmaceuticals-12-00054" ref-type="bibr">51</xref>,<xref rid="B55-pharmaceuticals-12-00054" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceuticals-12-00054" ref-type="bibr">56</xref>,<xref rid="B98-pharmaceuticals-12-00054" ref-type="bibr">98</xref>]. For a recent review of TRPA1 and its role in numerous pain states, including migraine, see [<xref rid="B58-pharmaceuticals-12-00054" ref-type="bibr">58</xref>] in this same Special Issue of Pharmaceuticals. Although the TRPA1 activator mustard oil had been used as a probe to cause pain responses from the meninges in rodents for a number of years (see [<xref rid="B99-pharmaceuticals-12-00054" ref-type="bibr">99</xref>,<xref rid="B100-pharmaceuticals-12-00054" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceuticals-12-00054" ref-type="bibr">101</xref>]), investigation of this channel in migraine expanded following a couple of key studies. One was the link between exposure to volatile oils from the <italic>Umbellularia californica</italic> tree (the &#x0201c;Headache Tree&#x0201d;) and headache attacks [<xref rid="B102-pharmaceuticals-12-00054" ref-type="bibr">102</xref>] which was followed by later studies showing that umbellulone activates TRPA1 and activation of TRPA1 in the dura by umbellulone and mustard oil causes headache responses in rats [<xref rid="B103-pharmaceuticals-12-00054" ref-type="bibr">103</xref>,<xref rid="B104-pharmaceuticals-12-00054" ref-type="bibr">104</xref>,<xref rid="B105-pharmaceuticals-12-00054" ref-type="bibr">105</xref>]. Umbellulone was also recently shown to facilitate propagation of CSD [<xref rid="B106-pharmaceuticals-12-00054" ref-type="bibr">106</xref>], so its actions, and that of TRPA1 in general, may not be restricted to peripheral sensory neurons and the meninges. This also led to several subsequent studies examining TRPA1-desensitizing compounds such as parthenolide from the feverfew herb and isopetasin from butterbur for their ability to desensitize meningeal nociceptors [<xref rid="B107-pharmaceuticals-12-00054" ref-type="bibr">107</xref>,<xref rid="B108-pharmaceuticals-12-00054" ref-type="bibr">108</xref>], potentially explaining the efficacy of these herbs in the treatment of migraine. Both of these studies show that these natural-product modulators of TRPA1 lead to functional desensitization of both the channel and the nerve ending expressing the channel. Consequences of this desensitization are decreased responses of nociceptive nerve endings to subsequent stimulation, which essentially acts as an inhibitor of neuronal function, and in the case of migraine, may lead to decreased noxious input from the meninges. The results of these studies suggest that compounds capable of desensitizing TRPA1 and TRPA1-expressing nerve endings may be viable new therapeutics for migraine.</p><p>The other key study leading to increased interest in TRPA1 and migraine was the finding that this channel mediates the vasodilatory response to inhalation of acrolein [<xref rid="B109-pharmaceuticals-12-00054" ref-type="bibr">109</xref>]. This was the first in a line of publications by these authors documenting and interaction between environmental irritants and TRPA1 that may lead to headaches following exposure. More recent work from these authors has shown that repeated exposure to acrolein potentiates meningeal vasodilatory responses to TRPA1 and TRPV1 activation [<xref rid="B110-pharmaceuticals-12-00054" ref-type="bibr">110</xref>] and leads to migraine-like cutaneous hypersensitivity and increased responses of the trigeminal afferent system to touch [<xref rid="B111-pharmaceuticals-12-00054" ref-type="bibr">111</xref>]. Further, lipidomic studies after acute or chronic inhalation of acrolein in rats found increased levels of a number of factors known to activate TRPV1 and TRPV4 [<xref rid="B112-pharmaceuticals-12-00054" ref-type="bibr">112</xref>]. These studies provide important mechanistic information for how repeated inhalation of environmental irritants can lead to headache disorders and also propose TRPA1 (as well as TRPV1 and TRPV4) antagonists as potential therapeutics in this area.</p><p>A number of studies over the last several years have been aimed at determining a role for TRPA1 in responses of the meningeal nociceptive system to other irritants such as hydrogen sulfide (H<sub>2</sub>S) as well as to nitric oxide (NO), both of which are well known to cause headaches. Importantly, these two compounds may act together as H<sub>2</sub>S and NO combine to form nitroxyl (HNO) that then reacts with and activates TRPA1 by covalent modification [<xref rid="B113-pharmaceuticals-12-00054" ref-type="bibr">113</xref>]. This reaction contributes to modulation of vascular tone downstream of H<sub>2</sub>S and NO via the HNO-activated and TRPA1-mediated release of CGRP. A recent study has demonstrated that this pathway contributes to activation of trigeminal afferent signaling [<xref rid="B114-pharmaceuticals-12-00054" ref-type="bibr">114</xref>] and can increase meningeal blood flow following topical administration if either NO or H<sub>2</sub>S donors onto the dura via the production of HNO [<xref rid="B115-pharmaceuticals-12-00054" ref-type="bibr">115</xref>]. However, this mechanism is far from fully explained as H<sub>2</sub>S-NO-TRPA1 pathway can also decrease activity in neurons of the spinal trigeminal nucleus, sometimes after prior activation [<xref rid="B116-pharmaceuticals-12-00054" ref-type="bibr">116</xref>]. Further, activation of TRPA1 alone (at least using acrolein) may not be sufficient to initiate afferent signaling from the meninges but may require co-activation of other channels such as TRPV1 [<xref rid="B117-pharmaceuticals-12-00054" ref-type="bibr">117</xref>]. Needless to say, these mechanisms are likely to be complex.</p><p>NO donors have long been recognized as migraine triggers, provoking attacks in approximately 75% of patients within 6 hours of administration [<xref rid="B118-pharmaceuticals-12-00054" ref-type="bibr">118</xref>,<xref rid="B119-pharmaceuticals-12-00054" ref-type="bibr">119</xref>]. However, the mechanisms by which this occurs remain poorly understood. Although one potential mechanism was described above (via formation of HNO), many other possibilities exist downstream of NO including activation of guanylyl cyclases, MAP kinases, nitrosylation of proteins, activation of cyclooxygenase enzymes, and production of peroxynitrite radicals [<xref rid="B120-pharmaceuticals-12-00054" ref-type="bibr">120</xref>,<xref rid="B121-pharmaceuticals-12-00054" ref-type="bibr">121</xref>,<xref rid="B122-pharmaceuticals-12-00054" ref-type="bibr">122</xref>,<xref rid="B123-pharmaceuticals-12-00054" ref-type="bibr">123</xref>,<xref rid="B124-pharmaceuticals-12-00054" ref-type="bibr">124</xref>,<xref rid="B125-pharmaceuticals-12-00054" ref-type="bibr">125</xref>]. As discussed above and also shown here [<xref rid="B126-pharmaceuticals-12-00054" ref-type="bibr">126</xref>], TRPA1 can mediate the nociceptive effects of NO, but given the diverse mechanisms downstream of NO and the diffusion of NO throughout all cells, its actions are likely complex. This question was extensively addressed recently using glyceryl trinitrate (GTN) administration to mice in the presence of pharmacological and genetic tools against TRPA1, aldehyde dehydrogenase, reactive oxygen and aldehyde species, and NADPH oxidase enzymes [<xref rid="B127-pharmaceuticals-12-00054" ref-type="bibr">127</xref>]. The authors examined both cutaneous facial vasodilation and allodynia following GTN and found that the initial vasodilation is TRPA1-independent, but is mediated by aldehyde dehydrogenase (which liberates NO from GTN) and a direct subsequent effect of NO on vessels. In contrast, the delayed allodynia following GTN was entirely dependent on TRPA1 expression. Activation of TRPA1 likely occurs due to direct NO-mediated interactions with the channel and also due to generation of reactive oxygen and carbonylic species from increased activity of NADPH oxidase in the trigeminal ganglion. Consistent with this study was another report showing that nitroglycerin can increase hyperalgesia in the orofacial formalin test in rats, an effect that was blocked by a TRPA1 antagonist, along with an increase in channel expression in the trigeminal ganglia, cervical spinal cord, and medulla [<xref rid="B128-pharmaceuticals-12-00054" ref-type="bibr">128</xref>]. These studies further implicates TRPA1 in migraine by directly demonstrating that it plays a role in headache-related behavior following exposure of one of the most reliable triggers of attacks.</p></sec></sec><sec id="sec5-pharmaceuticals-12-00054"><title>5. BoNTA, CGRP and TRP Channels</title><p>Interestingly, recent evidence points to the possible existence of interconnections between the action of BoNTA, the release of CGRP and the TRP channels. In particular, in a rat model of inflammation induced by complete Freund&#x02019;s adjuvant (CFA), it was demonstrated that pericranially-injected BoNTA is taken up by local sensory nerve endings, axonally transported to the trigeminal ganglion and transcytosed to dural afferents, where BoNTA-cleaved SNAP-25 colocalized with CGRP [<xref rid="B129-pharmaceuticals-12-00054" ref-type="bibr">129</xref>]. Importantly, BoNTA, similar to sumatriptan, reduced both the mechanical allodynia and the dural neurogenic inflammation evoked by CFA and this is likely to happen by the suppression of CGRP signalling [<xref rid="B129-pharmaceuticals-12-00054" ref-type="bibr">129</xref>]. Notably, it has been shown in migraine patients that CGRP levels after BoNTA treatment are significantly lower in comparison to the CGRP levels obtained before BoNTA treatment [<xref rid="B130-pharmaceuticals-12-00054" ref-type="bibr">130</xref>,<xref rid="B131-pharmaceuticals-12-00054" ref-type="bibr">131</xref>] and, more importantly, that the CGRP decrease is associated to the responsiveness to treatment. In fact, in responder patients, pretreatment CGRP levels were significantly higher than in nonresponders and, after treatment, the CGRP levels significantly decreased only in responders [<xref rid="B130-pharmaceuticals-12-00054" ref-type="bibr">130</xref>]. TRP channels, and especially TRPA1 and TRPV1, may also play a role in this scenario. It has been demonstrated that BoNTA inhibits TRPV1 trafficking to the plasma membrane in primary trigeminal ganglion neurons [<xref rid="B132-pharmaceuticals-12-00054" ref-type="bibr">132</xref>]. It has also been recently shown that the syntaxin 1-interacting protein, Munc18-1, is necessary for TRPV1-triggered CGRP release and for the response to the proinflammatory cytokine TNF&#x003b1;. Importantly, TNF&#x003b1; induces surface trafficking of TRPV1 and TRPA1 by means of a synaptic vesicle membrane protein, VAMP1, which is also essential for the exocytosis of CGRP. BoNTA inhibits the TNF&#x003b1;-elevated delivery and, consequently, abolishes the enhancement of Ca<sup>2+</sup> influx through the upregulated surface-expressed TRPV1 and TRPA1 channels [<xref rid="B133-pharmaceuticals-12-00054" ref-type="bibr">133</xref>]. In addition, in a rodent model, pretreatment with BoNTA significantly reduced both capsaicin- and allyl isothiocyanate (AITC)-induced pain for at least 21 days, suggesting a durable pain-preventative effect of BoNTA due to decreased responsiveness of TRPV1 and TRPA1 toward their selective agonists [<xref rid="B134-pharmaceuticals-12-00054" ref-type="bibr">134</xref>]. Finally, BoNT-A administered to tissues outside the calvaria, is able to inhibit responses of C-type meningeal nociceptors to stimulation of their intracranial dural receptive fields with capsaicin or mustard oil. BoNTA effects on capsaicin responses are greater when the dose is injected along the suture lines, instead of being divided between muscles and sutures [<xref rid="B135-pharmaceuticals-12-00054" ref-type="bibr">135</xref>], which is interesting from a translational point of view given that BoNTA is injected in both locations in patients.</p><p>Although conclusive evidence is still needed, one may hypothesize that the abovementioned mechanisms related to TRP channels contribute to the decreased release of CGRP associated to BoNTA; initial evidence of the role of this circuitry has also been emerging for other drugs. Both valproic acid and topiramate have been shown to inhibit the capsaicin-induced elevation of CGRP immunoreactivity in the trigeminal ganglia and CGRP depletion in the dura mater of rats, even if with some differences among adult and pediatric rats [<xref rid="B136-pharmaceuticals-12-00054" ref-type="bibr">136</xref>]. Finally, the pretreatment with valproic acid has been shown to attenuate the enhanced blood flow responses observed after inhalation of the TRPA1 agonist acrolein in a rodent model of chronic migraine [<xref rid="B111-pharmaceuticals-12-00054" ref-type="bibr">111</xref>]. Together, these studies support the concept that decreases in TRP channel-mediated release of CGRP and other neuropeptides may contribute to the efficacy of many pharmacological agents for migraine.</p></sec><sec id="sec6-pharmaceuticals-12-00054"><title>6. Concluding Remarks</title><p>There is currently a great deal of excitement in the migraine field due to the approval of several, new CGRP-based therapeutics for use in humans. These novel agents add to the toolkit of the headache specialist and offer new options with distinct mechanisms of action for patients. However, it is already clear that these new therapeutics are not a panacea as many patients get suboptimal relief from the monoclonal antibodies (approximately 35% showing less than 50% relief in an open-label study of erenumab [<xref rid="B137-pharmaceuticals-12-00054" ref-type="bibr">137</xref>]; similar results have been observed in studies with other antibodies [<xref rid="B138-pharmaceuticals-12-00054" ref-type="bibr">138</xref>]). While mechanisms determining what patients will or will not experience relief with these CGRP therapies remain unclear, there is still great need for new therapeutics and TRP channels may represent additional targets for these new drugs. Questions remain regarding the viability of TRP channels as drug targets for migraine and these questions require additional work among the research community. Although TRPV1 antagonists failed in a prior human trial for migraine, there is still a clear role for TRPV1 in the activation of meningeal nociceptors and thus potential for alternate therapeutics to show efficacy. Intranasal administration of the TRPV1 agonist Civamide was efficacious in humans, likely via desensitization of nociceptors [<xref rid="B139-pharmaceuticals-12-00054" ref-type="bibr">139</xref>], providing proof of concept for TRPV1 modulating therapeutics, in this case with an agonist. Little work currently exists surrounding TRPV4 and migraine and this is the area that needs to most future exploration to evaluate this channel as a potential anti-migraine drug target. The repeated identification of TRPM8 variants in GWAS supports continued interest in this channel for the disorder, but it remains unknown whether therapeutics should be agonists or antagonists. Better understanding of the impact of the channel mutations on expression/function will help determine this answer. Finally, TRPA1 represents one of the most promising targets for new therapeutics based on its potential role in headache following exposure to endogenous substances, reactive oxygen species, environmental irritants, and migraine triggers such as NO donors as well as its potential role in treating attacks when desensitized by natural products. As of this writing, few TRPA1 antagonists have been developed for testing in humans, but there is now strong preclinical rationale for testing of these agents, although no clinical trials are currently conducted to this aim (<uri xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</uri> accessed on February 17, 2019). Taken together, the data currently available surrounding TRP channels and migraine continue to make a compelling case for further development of new therapeutics based on modulation of these channels.</p></sec></body><back><notes><title>Funding</title><p>GD receives support from the National Institutes of Health (NS104200, NS104990, NS107058,NS098826) and grant support from Alder Biopharmaceuticals and Teva Pharmaceuticals.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest in relation to this review.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">TRP</td><td align="left" valign="middle" rowspan="1" colspan="1">Transient-receptor potential</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CGRP</td><td align="left" valign="middle" rowspan="1" colspan="1">Calcitonin gene-related peptide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BoNTA</td><td align="left" valign="middle" rowspan="1" colspan="1">onabotulinum toxin A</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IHS</td><td align="left" valign="middle" rowspan="1" colspan="1">International Headache Society</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICHD</td><td align="left" valign="middle" rowspan="1" colspan="1">International Classification of Headache Disorders</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GBD</td><td align="left" valign="middle" rowspan="1" colspan="1">Global Burden of Disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSAID</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-steroidal anti-inflammatory drugs</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACE</td><td align="left" valign="middle" rowspan="1" colspan="1">Angiotensin-converting enzyme</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GWAS</td><td align="left" valign="middle" rowspan="1" colspan="1">Genome-wide association study</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNP</td><td align="left" valign="middle" rowspan="1" colspan="1">Single nucleotide polymorphism</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RAMP</td><td align="left" valign="middle" rowspan="1" colspan="1">Receptor-activity modifying protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RCP</td><td align="left" valign="middle" rowspan="1" colspan="1">Receptor component protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PAR-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Protease-activated receptor type 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H<sub>2</sub>S</td><td align="left" valign="middle" rowspan="1" colspan="1">Hydrogen sulfide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NO</td><td align="left" valign="middle" rowspan="1" colspan="1">Nitric oxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HNO</td><td align="left" valign="middle" rowspan="1" colspan="1">Nitroxyl</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAP</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitogen-activated protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GTN</td><td align="left" valign="middle" rowspan="1" colspan="1">Glyceryl trinitrate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NADPH</td><td align="left" valign="middle" rowspan="1" colspan="1">Nicotinamide adenine dinucleotide phosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CFA</td><td align="left" valign="middle" rowspan="1" colspan="1">Complete Freund&#x02019;s adjuvant</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNAP-25</td><td align="left" valign="middle" rowspan="1" colspan="1">Synaptosomal-associated protein 25</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Munc</td><td align="left" valign="middle" rowspan="1" colspan="1">Mammalian uncoordinated</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VAMP</td><td align="left" valign="middle" rowspan="1" colspan="1">Vesicle-associated membrane protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor necrosis factor</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-12-00054"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodick</surname><given-names>D.W.</given-names></name></person-group><article-title>Migraine</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>1315</fpage><lpage>1330</lpage><?supplied-pmid 29523342?><pub-id pub-id-type="pmid">29523342</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-12-00054"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetvik</surname><given-names>K.G.</given-names></name><name><surname>MacGregor</surname><given-names>E.A.</given-names></name></person-group><article-title>Sex differences in the epidemiology, clinical features, and pathophysiology of migraine</article-title><source>Lancet Neurol.</source><year>2019</year><volume>16</volume><fpage>76</fpage><lpage>87</lpage></element-citation></ref><ref id="B3-pharmaceuticals-12-00054"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Headache Classification Committee of the International Headache Society (IHS)</collab></person-group><article-title>The International Classification of Headache Disorders, 3rd edition</article-title><source>Cephalalgia</source><year>2018</year><volume>38</volume><fpage>1</fpage><lpage>211</lpage></element-citation></ref><ref id="B4-pharmaceuticals-12-00054"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stovner</surname><given-names>L.J.</given-names></name><name><surname>Nichols</surname><given-names>E.</given-names></name><name><surname>Steiner</surname><given-names>T.J.</given-names></name><name><surname>Abd-Allah</surname><given-names>F.</given-names></name><name><surname>Abdelalim</surname><given-names>A.</given-names></name><name><surname>Al-Raddadi</surname><given-names>R.M.</given-names></name><name><surname>Ansha</surname><given-names>M.G.</given-names></name><name><surname>Barac</surname><given-names>A.</given-names></name><name><surname>Bensenor</surname><given-names>I.M.</given-names></name><name><surname>Doan</surname><given-names>L.P.</given-names></name><etal/></person-group><article-title>Global, regional, and national burden of migraine and tension-type headache, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016</article-title><source>Lancet Neurol.</source><year>2018</year><volume>17</volume><fpage>954</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">30353868</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-12-00054"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freilinger</surname><given-names>T.</given-names></name><name><surname>Anttila</surname><given-names>V.</given-names></name><name><surname>de Vries</surname><given-names>B.</given-names></name><name><surname>Malik</surname><given-names>R.</given-names></name><name><surname>Kallela</surname><given-names>M.</given-names></name><name><surname>Terwindt</surname><given-names>G.M.</given-names></name><name><surname>Pozo-Rosich</surname><given-names>P.</given-names></name><name><surname>Winsvold</surname><given-names>B.</given-names></name><name><surname>Nyholt</surname><given-names>D.R.</given-names></name><name><surname>van Oosterhout</surname><given-names>W.P.</given-names></name><etal/></person-group><article-title>Genome-wide association analysis identifies susceptibility loci for migraine without aura</article-title><source>Nat. Genet.</source><year>2012</year><volume>44</volume><fpage>777</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1038/ng.2307</pub-id><pub-id pub-id-type="pmid">22683712</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-12-00054"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenfeld</surname><given-names>A.M.</given-names></name><name><surname>Stark</surname><given-names>R.J.</given-names></name><name><surname>Freeman</surname><given-names>M.C.</given-names></name><name><surname>Orejudos</surname><given-names>A.</given-names></name><name><surname>Manack Adams</surname><given-names>A.</given-names></name></person-group><article-title>Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study</article-title><source>J. Headache Pain</source><year>2018</year><volume>19</volume><fpage>13</fpage><?supplied-pmid 29404713?><pub-id pub-id-type="pmid">29404713</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-12-00054"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Turkel</surname><given-names>C.C.</given-names></name><name><surname>DeGryse</surname><given-names>R.E.</given-names></name><name><surname>Aurora</surname><given-names>S.K.</given-names></name><name><surname>Silberstein</surname><given-names>S.D.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Diener</surname><given-names>H.C.</given-names></name><name><surname>Brin</surname><given-names>M.F.</given-names></name></person-group><article-title>OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program</article-title><source>Headache</source><year>2010</year><volume>50</volume><fpage>921</fpage><lpage>936</lpage><?supplied-pmid 20487038?><pub-id pub-id-type="pmid">20487038</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-12-00054"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charles</surname><given-names>A.</given-names></name></person-group><article-title>The pathophysiology of migraine: Implications for clinical management</article-title><source>Lancet Neurol.</source><year>2018</year><volume>17</volume><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">29229375</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-12-00054"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borsook</surname><given-names>D.</given-names></name><name><surname>Maleki</surname><given-names>N.</given-names></name><name><surname>Becerra</surname><given-names>L.</given-names></name><name><surname>McEwen</surname><given-names>B.</given-names></name></person-group><article-title>Understanding migraine through the lens of maladaptive stress responses: A model disease of allostatic load</article-title><source>Neuron</source><year>2012</year><volume>73</volume><fpage>219</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">22284178</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-12-00054"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noseda</surname><given-names>R.</given-names></name><name><surname>Burstein</surname><given-names>R.</given-names></name></person-group><article-title>Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain</article-title><source>Pain</source><year>2013</year><volume>154</volume><issue>Suppl. 1</issue><fpage>S44</fpage><lpage>S53</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2013.07.021</pub-id><pub-id pub-id-type="pmid">23891892</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-12-00054"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gormley</surname><given-names>P.</given-names></name><name><surname>Anttila</surname><given-names>V.</given-names></name><name><surname>Winsvold</surname><given-names>B.S.</given-names></name><name><surname>Palta</surname><given-names>P.</given-names></name><name><surname>Esko</surname><given-names>T.</given-names></name><name><surname>Pers</surname><given-names>T.H.</given-names></name><name><surname>Farh</surname><given-names>K.H.</given-names></name><name><surname>Cuenca-Leon</surname><given-names>E.</given-names></name><name><surname>Muona</surname><given-names>M.</given-names></name><name><surname>Furlotte</surname><given-names>N.A.</given-names></name><etal/></person-group><article-title>Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine</article-title><source>Nat. Genet.</source><year>2016</year><volume>48</volume><fpage>856</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1038/ng.3598</pub-id><?supplied-pmid 27322543?><pub-id pub-id-type="pmid">27322543</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-12-00054"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edvinsson</surname><given-names>L.</given-names></name><name><surname>Haanes</surname><given-names>K.A.</given-names></name><name><surname>Warfvinge</surname><given-names>K.</given-names></name><name><surname>Krause</surname><given-names>D.N.</given-names></name></person-group><article-title>CGRP as the target of new migraine therapies&#x02014;Successful translation from bench to clinic</article-title><source>Nat. Rev. Neurol.</source><year>2018</year><volume>14</volume><fpage>338</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/s41582-018-0003-1</pub-id><?supplied-pmid 29691490?><pub-id pub-id-type="pmid">29691490</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-12-00054"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Queiroz</surname><given-names>B.F.</given-names></name><name><surname>de Almeida</surname><given-names>M.P.</given-names></name><name><surname>Bakhle</surname><given-names>Y.S.</given-names></name><name><surname>Francischi</surname><given-names>J.N.</given-names></name></person-group><article-title>Calcitonin-gene related peptide is a potent inducer of oedema in rat orofacial tissue</article-title><source>Neuropeptides</source><year>2018</year><volume>68</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.npep.2018.01.004</pub-id><pub-id pub-id-type="pmid">29396376</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-12-00054"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukacs</surname><given-names>M.</given-names></name><name><surname>Haanes</surname><given-names>K.A.</given-names></name><name><surname>Majlath</surname><given-names>Z.</given-names></name><name><surname>Tajti</surname><given-names>J.</given-names></name><name><surname>Vecsei</surname><given-names>L.</given-names></name><name><surname>Warfvinge</surname><given-names>K.</given-names></name><name><surname>Edvinsson</surname><given-names>L.</given-names></name></person-group><article-title>Dural administration of inflammatory soup or Complete Freund&#x02019;s Adjuvant induces activation and inflammatory response in the rat trigeminal ganglion</article-title><source>J. Headache Pain</source><year>2015</year><volume>16</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1186/s10194-015-0564-y</pub-id><?supplied-pmid 26329487?><pub-id pub-id-type="pmid">26329487</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-12-00054"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>F.A.</given-names></name><name><surname>King</surname><given-names>R.</given-names></name><name><surname>Smillie</surname><given-names>S.J.</given-names></name><name><surname>Kodji</surname><given-names>X.</given-names></name><name><surname>Brain</surname><given-names>S.D.</given-names></name></person-group><article-title>Calcitonin gene-related peptide: Physiology and pathophysiology</article-title><source>Physiol. Rev.</source><year>2014</year><volume>94</volume><fpage>1099</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1152/physrev.00034.2013</pub-id><?supplied-pmid 25287861?><pub-id pub-id-type="pmid">25287861</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-12-00054"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulderry</surname><given-names>P.K.</given-names></name><name><surname>Ghatei</surname><given-names>M.A.</given-names></name><name><surname>Bishop</surname><given-names>A.E.</given-names></name><name><surname>Allen</surname><given-names>Y.S.</given-names></name><name><surname>Polak</surname><given-names>J.M.</given-names></name><name><surname>Bloom</surname><given-names>S.R.</given-names></name></person-group><article-title>Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat</article-title><source>Regul. Pept.</source><year>1985</year><volume>12</volume><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/0167-0115(85)90194-6</pub-id><pub-id pub-id-type="pmid">3877953</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-12-00054"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>S.J.</given-names></name><name><surname>Polak</surname><given-names>J.M.</given-names></name><name><surname>Bloom</surname><given-names>S.R.</given-names></name><name><surname>Sabate</surname><given-names>I.M.</given-names></name><name><surname>Mulderry</surname><given-names>P.M.</given-names></name><name><surname>Ghatei</surname><given-names>M.A.</given-names></name><name><surname>McGregor</surname><given-names>G.P.</given-names></name><name><surname>Morrison</surname><given-names>J.F.</given-names></name><name><surname>Kelly</surname><given-names>J.S.</given-names></name><name><surname>Evans</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species</article-title><source>J. Neurosci.</source><year>1984</year><volume>4</volume><fpage>3101</fpage><lpage>3111</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.04-12-03101.1984</pub-id><?supplied-pmid 6209366?><pub-id pub-id-type="pmid">6209366</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-12-00054"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eftekhari</surname><given-names>S.</given-names></name><name><surname>Salvatore</surname><given-names>C.A.</given-names></name><name><surname>Calamari</surname><given-names>A.</given-names></name><name><surname>Kane</surname><given-names>S.A.</given-names></name><name><surname>Tajti</surname><given-names>J.</given-names></name><name><surname>Edvinsson</surname><given-names>L.</given-names></name></person-group><article-title>Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion</article-title><source>Neuroscience</source><year>2010</year><volume>169</volume><fpage>683</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.05.016</pub-id><pub-id pub-id-type="pmid">20472035</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-12-00054"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallai</surname><given-names>V.</given-names></name><name><surname>Sarchielli</surname><given-names>P.</given-names></name><name><surname>Floridi</surname><given-names>A.</given-names></name><name><surname>Franceschini</surname><given-names>M.</given-names></name><name><surname>Codini</surname><given-names>M.</given-names></name><name><surname>Glioti</surname><given-names>G.</given-names></name><name><surname>Trequattrini</surname><given-names>A.</given-names></name><name><surname>Palumbo</surname><given-names>R.</given-names></name></person-group><article-title>Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally</article-title><source>Cephalalgia</source><year>1995</year><volume>15</volume><fpage>384</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1046/j.1468-29821995.1505384.x</pub-id><pub-id pub-id-type="pmid">8536297</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-12-00054"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cernuda-Morollon</surname><given-names>E.</given-names></name><name><surname>Larrosa</surname><given-names>D.</given-names></name><name><surname>Ramon</surname><given-names>C.</given-names></name><name><surname>Vega</surname><given-names>J.</given-names></name><name><surname>Martinez-Camblor</surname><given-names>P.</given-names></name><name><surname>Pascual</surname><given-names>J.</given-names></name></person-group><article-title>Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine</article-title><source>Neurology</source><year>2013</year><volume>81</volume><fpage>1191</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a6cb72</pub-id><pub-id pub-id-type="pmid">23975872</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-12-00054"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Edvinsson</surname><given-names>L.</given-names></name><name><surname>Ekman</surname><given-names>R.</given-names></name></person-group><article-title>Vasoactive peptide release in the extracerebral circulation of humans during migraine headache</article-title><source>Ann. Neurol.</source><year>1990</year><volume>28</volume><fpage>183</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1002/ana.410280213</pub-id><pub-id pub-id-type="pmid">1699472</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-12-00054"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Edvinsson</surname><given-names>L.</given-names></name></person-group><article-title>The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats</article-title><source>Ann. Neurol.</source><year>1993</year><volume>33</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1002/ana.410330109</pub-id><pub-id pub-id-type="pmid">8388188</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-12-00054"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarchielli</surname><given-names>P.</given-names></name><name><surname>Alberti</surname><given-names>A.</given-names></name><name><surname>Codini</surname><given-names>M.</given-names></name><name><surname>Floridi</surname><given-names>A.</given-names></name><name><surname>Gallai</surname><given-names>V.</given-names></name></person-group><article-title>Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks</article-title><source>Cephalalgia</source><year>2000</year><volume>20</volume><fpage>907</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2000.00146.x</pub-id><pub-id pub-id-type="pmid">11304026</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-12-00054"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juhasz</surname><given-names>G.</given-names></name><name><surname>Zsombok</surname><given-names>T.</given-names></name><name><surname>Jakab</surname><given-names>B.</given-names></name><name><surname>Nemeth</surname><given-names>J.</given-names></name><name><surname>Szolcsanyi</surname><given-names>J.</given-names></name><name><surname>Bagdy</surname><given-names>G.</given-names></name></person-group><article-title>Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack</article-title><source>Cephalalgia</source><year>2005</year><volume>25</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2005.00836.x</pub-id><pub-id pub-id-type="pmid">15689192</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-12-00054"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>L.H.</given-names></name><name><surname>Jacobsen</surname><given-names>V.B.</given-names></name><name><surname>Haderslev</surname><given-names>P.A.</given-names></name><name><surname>Sperling</surname><given-names>B.</given-names></name><name><surname>Iversen</surname><given-names>H.K.</given-names></name><name><surname>Olesen</surname><given-names>J.</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P.</given-names></name></person-group><article-title>Involvement of calcitonin gene-related peptide in migraine: Regional cerebral blood flow and blood flow velocity in migraine patients</article-title><source>J. Headache Pain</source><year>2008</year><volume>9</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1007/s10194-008-0036-8</pub-id><pub-id pub-id-type="pmid">18437288</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-12-00054"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>J.M.</given-names></name><name><surname>Hauge</surname><given-names>A.W.</given-names></name><name><surname>Olesen</surname><given-names>J.</given-names></name><name><surname>Ashina</surname><given-names>M.</given-names></name></person-group><article-title>Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura</article-title><source>Cephalalgia</source><year>2010</year><volume>30</volume><fpage>1179</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1177/0333102410368444</pub-id><pub-id pub-id-type="pmid">20855363</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-12-00054"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recober</surname><given-names>A.</given-names></name><name><surname>Kuburas</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wemmie</surname><given-names>J.A.</given-names></name><name><surname>Anderson</surname><given-names>M.G.</given-names></name><name><surname>Russo</surname><given-names>A.F.</given-names></name></person-group><article-title>Role of calcitonin gene-related peptide in light-aversive behavior: Implications for migraine</article-title><source>J. Neurosci.</source><year>2009</year><volume>29</volume><fpage>8798</fpage><lpage>8804</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1727-09.2009</pub-id><pub-id pub-id-type="pmid">19587287</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-12-00054"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J.</given-names></name><name><surname>Diener</surname><given-names>H.C.</given-names></name><name><surname>Husstedt</surname><given-names>I.W.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Hall</surname><given-names>D.</given-names></name><name><surname>Meier</surname><given-names>U.</given-names></name><name><surname>Pollentier</surname><given-names>S.</given-names></name><name><surname>Lesko</surname><given-names>L.M.</given-names></name></person-group><article-title>Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>350</volume><fpage>1104</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030505</pub-id><pub-id pub-id-type="pmid">15014183</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-12-00054"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>T.W.</given-names></name><name><surname>Ferrari</surname><given-names>M.D.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Galet</surname><given-names>V.</given-names></name><name><surname>Kost</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Leibensperger</surname><given-names>H.</given-names></name><name><surname>Froman</surname><given-names>S.</given-names></name><name><surname>Assaid</surname><given-names>C.</given-names></name><name><surname>Lines</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>2115</fpage><lpage>2123</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61626-8</pub-id><pub-id pub-id-type="pmid">19036425</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-12-00054"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connor</surname><given-names>K.M.</given-names></name><name><surname>Shapiro</surname><given-names>R.E.</given-names></name><name><surname>Diener</surname><given-names>H.C.</given-names></name><name><surname>Lucas</surname><given-names>S.</given-names></name><name><surname>Kost</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Fei</surname><given-names>K.</given-names></name><name><surname>Assaid</surname><given-names>C.</given-names></name><name><surname>Lines</surname><given-names>C.</given-names></name><name><surname>Ho</surname><given-names>T.W.</given-names></name></person-group><article-title>Randomized, controlled trial of telcagepant for the acute treatment of migraine</article-title><source>Neurology</source><year>2009</year><volume>73</volume><fpage>970</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b87942</pub-id><pub-id pub-id-type="pmid">19770473</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-12-00054"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname><given-names>T.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Dupre</surname><given-names>N.</given-names></name><name><surname>Ge</surname><given-names>J.Y.</given-names></name><name><surname>Bachman</surname><given-names>R.</given-names></name><name><surname>Assaid</surname><given-names>C.</given-names></name><name><surname>Aurora</surname><given-names>S.K.</given-names></name><name><surname>Michelson</surname><given-names>D.</given-names></name></person-group><article-title>A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine</article-title><source>Cephalalgia</source><year>2016</year><volume>36</volume><fpage>887</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1177/0333102416653233</pub-id><pub-id pub-id-type="pmid">27269043</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-12-00054"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>D.J.</given-names></name><name><surname>Aurora</surname><given-names>S.K.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Ge</surname><given-names>Y.J.</given-names></name><name><surname>Bachman</surname><given-names>R.</given-names></name><name><surname>Taraborelli</surname><given-names>D.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Assaid</surname><given-names>C.</given-names></name><name><surname>Lines</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine</article-title><source>Cephalalgia</source><year>2011</year><volume>31</volume><fpage>712</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1177/0333102411398399</pub-id><?supplied-pmid 21383045?><pub-id pub-id-type="pmid">21383045</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-12-00054"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>R.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Dodick</surname><given-names>D.</given-names></name><name><surname>Stock</surname><given-names>D.</given-names></name><name><surname>Manos</surname><given-names>G.</given-names></name><name><surname>Fischer</surname><given-names>T.Z.</given-names></name></person-group><article-title>BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial</article-title><source>Cephalalgia</source><year>2014</year><volume>34</volume><fpage>114</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1177/0333102413500727</pub-id><pub-id pub-id-type="pmid">23965396</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-12-00054"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Silberstein</surname><given-names>S.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Reuter</surname><given-names>U.</given-names></name><name><surname>Ashina</surname><given-names>M.</given-names></name><name><surname>Saper</surname><given-names>J.</given-names></name><name><surname>Cady</surname><given-names>R.</given-names></name><name><surname>Chon</surname><given-names>Y.</given-names></name><name><surname>Dietrich</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and efficacy of AMG 334 for prevention of episodic migraine: A randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet Neurol.</source><year>2016</year><volume>15</volume><fpage>382</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(16)00019-3</pub-id><pub-id pub-id-type="pmid">26879279</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-12-00054"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepper</surname><given-names>S.</given-names></name><name><surname>Ashina</surname><given-names>M.</given-names></name><name><surname>Reuter</surname><given-names>U.</given-names></name><name><surname>Brandes</surname><given-names>J.L.</given-names></name><name><surname>Dolezil</surname><given-names>D.</given-names></name><name><surname>Silberstein</surname><given-names>S.</given-names></name><name><surname>Winner</surname><given-names>P.</given-names></name><name><surname>Leonardi</surname><given-names>D.</given-names></name><name><surname>Mikol</surname><given-names>D.</given-names></name><name><surname>Lenz</surname><given-names>R.</given-names></name></person-group><article-title>Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial</article-title><source>Lancet Neurol.</source><year>2017</year><volume>16</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(17)30083-2</pub-id><pub-id pub-id-type="pmid">28460892</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-12-00054"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Reuter</surname><given-names>U.</given-names></name><name><surname>Hallstrom</surname><given-names>Y.</given-names></name><name><surname>Broessner</surname><given-names>G.</given-names></name><name><surname>Bonner</surname><given-names>J.H.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Sapra</surname><given-names>S.</given-names></name><name><surname>Picard</surname><given-names>H.</given-names></name><name><surname>Mikol</surname><given-names>D.D.</given-names></name><name><surname>Lenz</surname><given-names>R.A.</given-names></name></person-group><article-title>A Controlled Trial of Erenumab for Episodic Migraine</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>2123</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1705848</pub-id><pub-id pub-id-type="pmid">29171821</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-12-00054"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Silberstein</surname><given-names>S.D.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Olesen</surname><given-names>J.</given-names></name><name><surname>Ashina</surname><given-names>M.</given-names></name><name><surname>Wilks</surname><given-names>K.</given-names></name><name><surname>Kudrow</surname><given-names>D.</given-names></name><name><surname>Kroll</surname><given-names>R.</given-names></name><name><surname>Kohrman</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial</article-title><source>Lancet Neurol.</source><year>2014</year><volume>13</volume><fpage>1100</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70209-1</pub-id><pub-id pub-id-type="pmid">25297013</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-12-00054"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigal</surname><given-names>M.E.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Rapoport</surname><given-names>A.M.</given-names></name><name><surname>Silberstein</surname><given-names>S.D.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Loupe</surname><given-names>P.S.</given-names></name><name><surname>Burstein</surname><given-names>R.</given-names></name><name><surname>Newman</surname><given-names>L.C.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name></person-group><article-title>Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study</article-title><source>Lancet Neurol.</source><year>2015</year><volume>14</volume><fpage>1081</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)00249-5</pub-id><pub-id pub-id-type="pmid">26432182</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-12-00054"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigal</surname><given-names>M.E.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Krymchantowski</surname><given-names>A.V.</given-names></name><name><surname>VanderPluym</surname><given-names>J.H.</given-names></name><name><surname>Tepper</surname><given-names>S.J.</given-names></name><name><surname>Aycardi</surname><given-names>E.</given-names></name><name><surname>Loupe</surname><given-names>P.S.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name></person-group><article-title>TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points</article-title><source>Neurology</source><year>2016</year><volume>87</volume><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002801</pub-id><pub-id pub-id-type="pmid">27281531</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-12-00054"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>S.D.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Bigal</surname><given-names>M.E.</given-names></name><name><surname>Yeung</surname><given-names>P.P.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Blankenbiller</surname><given-names>T.</given-names></name><name><surname>Grozinski-Wolff</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Aycardi</surname><given-names>E.</given-names></name></person-group><article-title>Fremanezumab for the Preventive Treatment of Chronic Migraine</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>2113</fpage><lpage>2122</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1709038</pub-id><?supplied-pmid 29171818?><pub-id pub-id-type="pmid">29171818</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-12-00054"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Silberstein</surname><given-names>S.D.</given-names></name><name><surname>Bigal</surname><given-names>M.E.</given-names></name><name><surname>Yeung</surname><given-names>P.P.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Blankenbiller</surname><given-names>T.</given-names></name><name><surname>Grozinski-Wolff</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Aycardi</surname><given-names>E.</given-names></name></person-group><article-title>Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial</article-title><source>Jama</source><year>2018</year><volume>319</volume><fpage>1999</fpage><lpage>2008</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.4853</pub-id><pub-id pub-id-type="pmid">29800211</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-12-00054"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Spierings</surname><given-names>E.L.</given-names></name><name><surname>Scherer</surname><given-names>J.C.</given-names></name><name><surname>Sweeney</surname><given-names>S.P.</given-names></name><name><surname>Grayzel</surname><given-names>D.S.</given-names></name></person-group><article-title>Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomised, double-blind, placebo-controlled study</article-title><source>Lancet Neurol.</source><year>2014</year><volume>13</volume><fpage>885</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70128-0</pub-id><pub-id pub-id-type="pmid">25127173</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-12-00054"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skljarevski</surname><given-names>V.</given-names></name><name><surname>Oakes</surname><given-names>T.M.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Ferguson</surname><given-names>M.B.</given-names></name><name><surname>Martinez</surname><given-names>J.</given-names></name><name><surname>Camporeale</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>K.W.</given-names></name><name><surname>Shan</surname><given-names>Q.</given-names></name><name><surname>Carter</surname><given-names>J.</given-names></name><name><surname>Schacht</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial</article-title><source>JAMA Neurol.</source><year>2018</year><volume>75</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2017.3859</pub-id><pub-id pub-id-type="pmid">29255900</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-12-00054"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stauffer</surname><given-names>V.L.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Carter</surname><given-names>J.N.</given-names></name><name><surname>Ailani</surname><given-names>J.</given-names></name><name><surname>Conley</surname><given-names>R.R.</given-names></name></person-group><article-title>Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial</article-title><source>JAMA Neurol.</source><year>2018</year><volume>75</volume><fpage>1080</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2018.1212</pub-id><pub-id pub-id-type="pmid">29813147</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-12-00054"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skljarevski</surname><given-names>V.</given-names></name><name><surname>Matharu</surname><given-names>M.</given-names></name><name><surname>Millen</surname><given-names>B.A.</given-names></name><name><surname>Ossipov</surname><given-names>M.H.</given-names></name><name><surname>Kim</surname><given-names>B.K.</given-names></name><name><surname>Yang</surname><given-names>J.Y.</given-names></name></person-group><article-title>Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial</article-title><source>Cephalalgia</source><year>2018</year><volume>38</volume><fpage>1442</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1177/0333102418779543</pub-id><pub-id pub-id-type="pmid">29848108</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-12-00054"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>C.</given-names></name><name><surname>Burstein</surname><given-names>R.</given-names></name></person-group><article-title>Sensitization of the trigeminovascular pathway: Perspective and implications to migraine pathophysiology</article-title><source>J. Cl.in Neurol.</source><year>2012</year><volume>8</volume><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.3988/jcn.2012.8.2.89</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-12-00054"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Mohammad Amin</surname><given-names>F.</given-names></name><name><surname>Emil Christensen</surname><given-names>C.</given-names></name><name><surname>Ghanizada</surname><given-names>H.</given-names></name><name><surname>Younis</surname><given-names>S.</given-names></name><name><surname>Olinger</surname><given-names>A.C.R.</given-names></name><name><surname>de Koning</surname><given-names>P.J.H.</given-names></name><name><surname>Larsson</surname><given-names>H.B.W.</given-names></name><name><surname>Ashina</surname><given-names>M.</given-names></name></person-group><article-title>Meningeal contribution to migraine pain: A magnetic resonance angiography study</article-title><source>Brain</source><year>2019</year><volume>142</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1093/brain/awy300</pub-id><pub-id pub-id-type="pmid">30590467</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-12-00054"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vriens</surname><given-names>J.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name><name><surname>Nilius</surname><given-names>B.</given-names></name></person-group><article-title>Pharmacology of vanilloid transient receptor potential cation channels</article-title><source>Mol. Pharmacol.</source><year>2009</year><volume>75</volume><fpage>1262</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1124/mol.109.055624</pub-id><pub-id pub-id-type="pmid">19297520</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-12-00054"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julius</surname><given-names>D.</given-names></name></person-group><article-title>TRP channels and pain</article-title><source>Annu. Rev. Cell Dev. Biol.</source><year>2013</year><volume>29</volume><fpage>355</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1146/annurev-cellbio-101011-155833</pub-id><pub-id pub-id-type="pmid">24099085</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-12-00054"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardin</surname><given-names>I.</given-names></name><name><surname>Lopez</surname><given-names>J.J.</given-names></name><name><surname>Diez</surname><given-names>R.</given-names></name><name><surname>Sanchez-Collado</surname><given-names>J.</given-names></name><name><surname>Cantonero</surname><given-names>C.</given-names></name><name><surname>Albarran</surname><given-names>L.</given-names></name><name><surname>Woodard</surname><given-names>G.E.</given-names></name><name><surname>Redondo</surname><given-names>P.C.</given-names></name><name><surname>Salido</surname><given-names>G.M.</given-names></name><name><surname>Smani</surname><given-names>T.</given-names></name><etal/></person-group><article-title>TRPs in Pain Sensation</article-title><source>Front. Physiol.</source><year>2017</year><volume>8</volume><fpage>392</fpage><pub-id pub-id-type="doi">10.3389/fphys.2017.00392</pub-id><pub-id pub-id-type="pmid">28649203</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-12-00054"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dussor</surname><given-names>G.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>J.Y.</given-names></name><name><surname>Ossipov</surname><given-names>M.H.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><name><surname>Porreca</surname><given-names>F.</given-names></name></person-group><article-title>Targeting TRP channels for novel migraine therapeutics</article-title><source>ACS Chem. Neurosci.</source><year>2014</year><volume>5</volume><fpage>1085</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1021/cn500083e</pub-id><pub-id pub-id-type="pmid">25138211</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-12-00054"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhuis</surname><given-names>N.A.</given-names></name><name><surname>Poole</surname><given-names>D.P.</given-names></name><name><surname>Grace</surname><given-names>M.</given-names></name><name><surname>McIntyre</surname><given-names>P.</given-names></name><name><surname>Bunnett</surname><given-names>N.W.</given-names></name></person-group><article-title>The G protein-coupled receptor-transient receptor potential channel axis: Molecular insights for targeting disorders of sensation and inflammation</article-title><source>Pharmacol. Rev.</source><year>2015</year><volume>67</volume><fpage>36</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1124/pr.114.009555</pub-id><pub-id pub-id-type="pmid">25361914</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-12-00054"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dussor</surname><given-names>G.</given-names></name><name><surname>Cao</surname><given-names>Y.Q.</given-names></name></person-group><article-title>TRPM8 and Migraine</article-title><source>Headache</source><year>2016</year><volume>56</volume><fpage>1406</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.1111/head.12948</pub-id><pub-id pub-id-type="pmid">27634619</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-12-00054"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geppetti</surname><given-names>P.</given-names></name><name><surname>Benemei</surname><given-names>S.</given-names></name><name><surname>De Cesaris</surname><given-names>F.</given-names></name></person-group><article-title>CGRP receptors and TRP channels in migraine</article-title><source>J. Headache Pain</source><year>2015</year><volume>16</volume><fpage>A21</fpage><pub-id pub-id-type="doi">10.1186/1129-2377-16-S1-A21</pub-id><pub-id pub-id-type="pmid">28132367</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-12-00054"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benemei</surname><given-names>S.</given-names></name><name><surname>De Cesaris</surname><given-names>F.</given-names></name><name><surname>Fusi</surname><given-names>C.</given-names></name><name><surname>Rossi</surname><given-names>E.</given-names></name><name><surname>Lupi</surname><given-names>C.</given-names></name><name><surname>Geppetti</surname><given-names>P.</given-names></name></person-group><article-title>TRPA1 and other TRP channels in migraine</article-title><source>J. Headache Pain</source><year>2013</year><volume>14</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/1129-2377-14-71</pub-id><pub-id pub-id-type="pmid">23941062</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-12-00054"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benemei</surname><given-names>S.</given-names></name><name><surname>Fusi</surname><given-names>C.</given-names></name><name><surname>Trevisan</surname><given-names>G.</given-names></name><name><surname>Geppetti</surname><given-names>P.</given-names></name></person-group><article-title>The TRPA1 channel in migraine mechanism and treatment</article-title><source>Br. J. Pharmacol.</source><year>2014</year><volume>171</volume><fpage>2552</fpage><lpage>2567</lpage><pub-id pub-id-type="doi">10.1111/bph.12512</pub-id><pub-id pub-id-type="pmid">24206166</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-12-00054"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dux</surname><given-names>M.</given-names></name><name><surname>Santha</surname><given-names>P.</given-names></name><name><surname>Jancso</surname><given-names>G.</given-names></name></person-group><article-title>The role of chemosensitive afferent nerves and TRP ion channels in the pathomechanism of headaches</article-title><source>Pflug. Arch.</source><year>2012</year><volume>464</volume><fpage>239</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1007/s00424-012-1142-7</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-12-00054"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koivisto</surname><given-names>A.</given-names></name><name><surname>Jalava</surname><given-names>N.</given-names></name><name><surname>Bratty</surname><given-names>R.</given-names></name><name><surname>Pertovaara</surname><given-names>A.</given-names></name></person-group><article-title>TRPA1 Antagonists for Pain Relief</article-title><source>Pharmaceuticals</source><year>2018</year><volume>11</volume><elocation-id>117</elocation-id><pub-id pub-id-type="doi">10.3390/ph11040117</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-12-00054"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moskowitz</surname><given-names>M.A.</given-names></name><name><surname>Brody</surname><given-names>M.</given-names></name><name><surname>Liu-Chen</surname><given-names>L.Y.</given-names></name></person-group><article-title>In vitro release of immunoreactive substance P from putative afferent nerve endings in bovine pia arachnoid</article-title><source>Neuroscience</source><year>1983</year><volume>9</volume><fpage>809</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(83)90269-5</pub-id><pub-id pub-id-type="pmid">6194478</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-12-00054"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>T.</given-names></name><name><surname>Toriumi</surname><given-names>H.</given-names></name><name><surname>Sato</surname><given-names>H.</given-names></name><name><surname>Shibata</surname><given-names>M.</given-names></name><name><surname>Nagata</surname><given-names>E.</given-names></name><name><surname>Gotoh</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>N.</given-names></name></person-group><article-title>Distribution and origin of TRPV1 receptor-containing nerve fibers in the dura mater of rat</article-title><source>Brain Res.</source><year>2007</year><volume>1173</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2007.07.068</pub-id><pub-id pub-id-type="pmid">17765209</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-12-00054"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Fiacco</surname><given-names>M.</given-names></name><name><surname>Quartu</surname><given-names>M.</given-names></name><name><surname>Boi</surname><given-names>M.</given-names></name><name><surname>Serra</surname><given-names>M.P.</given-names></name><name><surname>Melis</surname><given-names>T.</given-names></name><name><surname>Boccaletti</surname><given-names>R.</given-names></name><name><surname>Shevel</surname><given-names>E.</given-names></name><name><surname>Cianchetti</surname><given-names>C.</given-names></name></person-group><article-title>TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2015</year><volume>86</volume><fpage>393</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2014-308813</pub-id><pub-id pub-id-type="pmid">25288608</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-12-00054"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buonvicino</surname><given-names>D.</given-names></name><name><surname>Urru</surname><given-names>M.</given-names></name><name><surname>Muzzi</surname><given-names>M.</given-names></name><name><surname>Ranieri</surname><given-names>G.</given-names></name><name><surname>Luceri</surname><given-names>C.</given-names></name><name><surname>Oteri</surname><given-names>C.</given-names></name><name><surname>Lapucci</surname><given-names>A.</given-names></name><name><surname>Chiarugi</surname><given-names>A.</given-names></name></person-group><article-title>Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns</article-title><source>Pain</source><year>2018</year><volume>159</volume><fpage>1980</fpage><lpage>1988</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000001291</pub-id><pub-id pub-id-type="pmid">29794878</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-12-00054"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marics</surname><given-names>B.</given-names></name><name><surname>Peitl</surname><given-names>B.</given-names></name><name><surname>Pazmandi</surname><given-names>K.</given-names></name><name><surname>Bacsi</surname><given-names>A.</given-names></name><name><surname>Nemeth</surname><given-names>J.</given-names></name><name><surname>Oszlacs</surname><given-names>O.</given-names></name><name><surname>Jancso</surname><given-names>G.</given-names></name><name><surname>Dux</surname><given-names>M.</given-names></name></person-group><article-title>Diet-Induced Obesity Enhances TRPV1-Mediated Neurovascular Reactions in the Dura Mater</article-title><source>Headache</source><year>2017</year><volume>57</volume><fpage>441</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1111/head.13033</pub-id><pub-id pub-id-type="pmid">28133727</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-12-00054"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>H.L.</given-names></name><name><surname>Broadhurst</surname><given-names>K.A.</given-names></name><name><surname>Luu</surname><given-names>A.S.</given-names></name><name><surname>Lara</surname><given-names>O.</given-names></name><name><surname>Kothari</surname><given-names>S.D.</given-names></name><name><surname>Mohapatra</surname><given-names>D.P.</given-names></name><name><surname>Recober</surname><given-names>A.</given-names></name></person-group><article-title>Abnormal trigeminal sensory processing in obese mice</article-title><source>Pain</source><year>2016</year><volume>157</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000355</pub-id><pub-id pub-id-type="pmid">26397933</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-12-00054"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marics</surname><given-names>B.</given-names></name><name><surname>Peitl</surname><given-names>B.</given-names></name><name><surname>Varga</surname><given-names>A.</given-names></name><name><surname>Pazmandi</surname><given-names>K.</given-names></name><name><surname>Bacsi</surname><given-names>A.</given-names></name><name><surname>Nemeth</surname><given-names>J.</given-names></name><name><surname>Szilvassy</surname><given-names>Z.</given-names></name><name><surname>Jancso</surname><given-names>G.</given-names></name><name><surname>Dux</surname><given-names>M.</given-names></name></person-group><article-title>Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses</article-title><source>Cephalalgia</source><year>2017</year><volume>37</volume><fpage>581</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1177/0333102416654883</pub-id><pub-id pub-id-type="pmid">27301459</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-12-00054"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahimi</surname><given-names>K.</given-names></name><name><surname>Vermeersch</surname><given-names>S.</given-names></name><name><surname>Danser</surname><given-names>A.</given-names></name><name><surname>Villalon</surname><given-names>C.M.</given-names></name><name><surname>van den Meiracker</surname><given-names>A.H.</given-names></name><name><surname>de Hoon</surname><given-names>J.</given-names></name><name><surname>MaassenVanDenBrink</surname><given-names>A.</given-names></name></person-group><article-title>Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead</article-title><source>Cephalalgia</source><year>2014</year><volume>34</volume><fpage>514</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1177/0333102413517773</pub-id><pub-id pub-id-type="pmid">24391116</pub-id></element-citation></ref><ref id="B67-pharmaceuticals-12-00054"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahimi</surname><given-names>K.</given-names></name><name><surname>Vermeersch</surname><given-names>S.</given-names></name><name><surname>Frederiks</surname><given-names>P.</given-names></name><name><surname>Geldhof</surname><given-names>V.</given-names></name><name><surname>Draulans</surname><given-names>C.</given-names></name><name><surname>Buntinx</surname><given-names>L.</given-names></name><name><surname>Lesaffre</surname><given-names>E.</given-names></name><name><surname>MaassenVanDenBrink</surname><given-names>A.</given-names></name><name><surname>de Hoon</surname><given-names>J.</given-names></name></person-group><article-title>The influence of migraine and female hormones on capsaicin-induced dermal blood flow</article-title><source>Cephalalgia</source><year>2017</year><volume>37</volume><fpage>1164</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1177/0333102416668659</pub-id><pub-id pub-id-type="pmid">27687880</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-12-00054"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamshilin</surname><given-names>A.A.</given-names></name><name><surname>Volynsky</surname><given-names>M.A.</given-names></name><name><surname>Khayrutdinova</surname><given-names>O.</given-names></name><name><surname>Nurkhametova</surname><given-names>D.</given-names></name><name><surname>Babayan</surname><given-names>L.</given-names></name><name><surname>Amelin</surname><given-names>A.V.</given-names></name><name><surname>Mamontov</surname><given-names>O.V.</given-names></name><name><surname>Giniatullin</surname><given-names>R.</given-names></name></person-group><article-title>Novel capsaicin-induced parameters of microcirculation in migraine patients revealed by imaging photoplethysmography</article-title><source>J. Headache Pain</source><year>2018</year><volume>19</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s10194-018-0872-0</pub-id><pub-id pub-id-type="pmid">29915934</pub-id></element-citation></ref><ref id="B69-pharmaceuticals-12-00054"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Levy</surname><given-names>D.</given-names></name><name><surname>Noseda</surname><given-names>R.</given-names></name><name><surname>Kainz</surname><given-names>V.</given-names></name><name><surname>Jakubowski</surname><given-names>M.</given-names></name><name><surname>Burstein</surname><given-names>R.</given-names></name></person-group><article-title>Activation of meningeal nociceptors by cortical spreading depression: Implications for migraine with aura</article-title><source>J. Neurosci.</source><year>2010</year><volume>30</volume><fpage>8807</fpage><lpage>8814</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0511-10.2010</pub-id><pub-id pub-id-type="pmid">20592202</pub-id></element-citation></ref><ref id="B70-pharmaceuticals-12-00054"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.C.</given-names></name><name><surname>Levy</surname><given-names>D.</given-names></name><name><surname>Kainz</surname><given-names>V.</given-names></name><name><surname>Noseda</surname><given-names>R.</given-names></name><name><surname>Jakubowski</surname><given-names>M.</given-names></name><name><surname>Burstein</surname><given-names>R.</given-names></name></person-group><article-title>Activation of Central Trigeminovascular Neurons by Cortical Spreading Depression</article-title><source>Ann. Neurol.</source><year>2011</year><volume>69</volume><fpage>855</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1002/ana.22329</pub-id><pub-id pub-id-type="pmid">21416489</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-12-00054"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schain</surname><given-names>A.J.</given-names></name><name><surname>Melo-Carrillo</surname><given-names>A.</given-names></name><name><surname>Borsook</surname><given-names>D.</given-names></name><name><surname>Grutzendler</surname><given-names>J.</given-names></name><name><surname>Strassman</surname><given-names>A.M.</given-names></name><name><surname>Burstein</surname><given-names>R.</given-names></name></person-group><article-title>Activation of pial and dural macrophages and dendritic cells by cortical spreading depression</article-title><source>Ann. Neurol.</source><year>2018</year><volume>83</volume><fpage>508</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1002/ana.25169</pub-id><pub-id pub-id-type="pmid">29394508</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-12-00054"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karatas</surname><given-names>H.</given-names></name><name><surname>Erdener</surname><given-names>S.E.</given-names></name><name><surname>Gursoy-Ozdemir</surname><given-names>Y.</given-names></name><name><surname>Lule</surname><given-names>S.</given-names></name><name><surname>Eren-Kocak</surname><given-names>E.</given-names></name><name><surname>Sen</surname><given-names>Z.D.</given-names></name><name><surname>Dalkara</surname><given-names>T.</given-names></name></person-group><article-title>Spreading Depression Triggers Headache by Activating Neuronal Panx1 Channels</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>1092</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1126/science.1231897</pub-id><pub-id pub-id-type="pmid">23449592</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-12-00054"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D.</given-names></name></person-group><article-title>Endogenous mechanisms underlying the activation and sensitization of meningeal nociceptors: The role of immuno-vascular interactions and cortical spreading depression</article-title><source>Curr. Pain Headache Rep.</source><year>2012</year><volume>16</volume><fpage>270</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1007/s11916-012-0255-1</pub-id><pub-id pub-id-type="pmid">22328144</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-12-00054"><label>74.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>C.B.</given-names></name><name><surname>Lai</surname><given-names>R.</given-names></name><name><surname>Guillard</surname><given-names>F.</given-names></name><name><surname>Bullman</surname><given-names>J.</given-names></name><name><surname>Baines</surname><given-names>A.</given-names></name><name><surname>Napolitano</surname><given-names>A.</given-names></name><name><surname>Appleby</surname><given-names>J.</given-names></name></person-group><article-title>A randomised, two-period cross-over study to investigate the efficacy of the TRPV1 antagonist SB-705498 in acute migraine</article-title><source>Proceedings of the yje Pain in Europe VI</source><conf-loc>Lisbon, Portugal</conf-loc><conf-date>9&#x02013;12 September 2009</conf-date><fpage>702</fpage></element-citation></ref><ref id="B75-pharmaceuticals-12-00054"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedtke</surname><given-names>W.</given-names></name><name><surname>Choe</surname><given-names>Y.</given-names></name><name><surname>Marti-Renom</surname><given-names>M.A.</given-names></name><name><surname>Bell</surname><given-names>A.M.</given-names></name><name><surname>Denis</surname><given-names>C.S.</given-names></name><name><surname>Sali</surname><given-names>A.</given-names></name><name><surname>Hudspeth</surname><given-names>A.J.</given-names></name><name><surname>Friedman</surname><given-names>J.M.</given-names></name><name><surname>Heller</surname><given-names>S.</given-names></name></person-group><article-title>Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor</article-title><source>Cell</source><year>2000</year><volume>103</volume><fpage>525</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00143-4</pub-id><pub-id pub-id-type="pmid">11081638</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-12-00054"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedtke</surname><given-names>W.</given-names></name><name><surname>Tobin</surname><given-names>D.M.</given-names></name><name><surname>Bargmann</surname><given-names>C.I.</given-names></name><name><surname>Friedman</surname><given-names>J.M.</given-names></name></person-group><article-title>Mammalian TRPV4 (VR-OAC) directs behavioral responses to osmotic and mechanical stimuli in Caenorhabditis elegans</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><issue>Suppl. 2</issue><fpage>14531</fpage><lpage>14536</lpage><pub-id pub-id-type="doi">10.1073/pnas.2235619100</pub-id><pub-id pub-id-type="pmid">14581619</pub-id></element-citation></ref><ref id="B77-pharmaceuticals-12-00054"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vriens</surname><given-names>J.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Janssens</surname><given-names>A.</given-names></name><name><surname>Droogmans</surname><given-names>G.</given-names></name><name><surname>Voets</surname><given-names>T.</given-names></name><name><surname>Nilius</surname><given-names>B.</given-names></name></person-group><article-title>Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1073/pnas.0303329101</pub-id><pub-id pub-id-type="pmid">14691263</pub-id></element-citation></ref><ref id="B78-pharmaceuticals-12-00054"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>R.</given-names></name><name><surname>Cutrer</surname><given-names>M.F.</given-names></name><name><surname>Yarnitsky</surname><given-names>D.</given-names></name></person-group><article-title>The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine</article-title><source>Brain J. Neurol.</source><year>2000</year><volume>123</volume><issue-part>Pt 8</issue-part><fpage>1703</fpage><lpage>1709</lpage><pub-id pub-id-type="doi">10.1093/brain/123.8.1703</pub-id></element-citation></ref><ref id="B79-pharmaceuticals-12-00054"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>M.M.</given-names></name></person-group><article-title>TRP Channels as Potential Drug Targets</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2018</year><volume>58</volume><fpage>309</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010617-052832</pub-id><pub-id pub-id-type="pmid">28945977</pub-id></element-citation></ref><ref id="B80-pharmaceuticals-12-00054"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Edelmayer</surname><given-names>R.M.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Dussor</surname><given-names>G.</given-names></name></person-group><article-title>Activation of TRPV4 on dural afferents produces headache-related behavior in a preclinical rat model</article-title><source>Cephalalgia</source><year>2011</year><volume>31</volume><fpage>1595</fpage><lpage>1600</lpage><pub-id pub-id-type="doi">10.1177/0333102411427600</pub-id><pub-id pub-id-type="pmid">22049072</pub-id></element-citation></ref><ref id="B81-pharmaceuticals-12-00054"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cenac</surname><given-names>N.</given-names></name><name><surname>Altier</surname><given-names>C.</given-names></name><name><surname>Chapman</surname><given-names>K.</given-names></name><name><surname>Liedtke</surname><given-names>W.</given-names></name><name><surname>Zamponi</surname><given-names>G.</given-names></name><name><surname>Vergnolle</surname><given-names>N.</given-names></name></person-group><article-title>Transient receptor potential vanilloid-4 has a major role in visceral hypersensitivity symptoms</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><fpage>937</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.05.024</pub-id><pub-id pub-id-type="pmid">18565335</pub-id></element-citation></ref><ref id="B82-pharmaceuticals-12-00054"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>A.D.</given-names></name><name><surname>Cottrell</surname><given-names>G.S.</given-names></name><name><surname>Amadesi</surname><given-names>S.</given-names></name><name><surname>Trevisani</surname><given-names>M.</given-names></name><name><surname>Nicoletti</surname><given-names>P.</given-names></name><name><surname>Materazzi</surname><given-names>S.</given-names></name><name><surname>Altier</surname><given-names>C.</given-names></name><name><surname>Cenac</surname><given-names>N.</given-names></name><name><surname>Zamponi</surname><given-names>G.W.</given-names></name><name><surname>Bautista-Cruz</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice</article-title><source>J. Physiol.</source><year>2007</year><volume>578</volume><fpage>715</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2006.121111</pub-id><pub-id pub-id-type="pmid">17124270</pub-id></element-citation></ref><ref id="B83-pharmaceuticals-12-00054"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sipe</surname><given-names>W.E.</given-names></name><name><surname>Brierley</surname><given-names>S.M.</given-names></name><name><surname>Martin</surname><given-names>C.M.</given-names></name><name><surname>Phillis</surname><given-names>B.D.</given-names></name><name><surname>Cruz</surname><given-names>F.B.</given-names></name><name><surname>Grady</surname><given-names>E.F.</given-names></name><name><surname>Liedtke</surname><given-names>W.</given-names></name><name><surname>Cohen</surname><given-names>D.M.</given-names></name><name><surname>Vanner</surname><given-names>S.</given-names></name><name><surname>Blackshaw</surname><given-names>L.A.</given-names></name><etal/></person-group><article-title>Transient receptor potential vanilloid 4 mediates protease activated receptor 2-induced sensitization of colonic afferent nerves and visceral hyperalgesia</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2008</year><volume>294</volume><fpage>G1288</fpage><lpage>G1298</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00002.2008</pub-id><pub-id pub-id-type="pmid">18325985</pub-id></element-citation></ref><ref id="B84-pharmaceuticals-12-00054"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.C.</given-names></name><name><surname>Levy</surname><given-names>D.</given-names></name></person-group><article-title>Modulation of meningeal nociceptors mechanosensitivity by peripheral proteinase-activated receptor-2: The role of mast cells</article-title><source>Cephalalgia</source><year>2008</year><volume>28</volume><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2007.01523.x</pub-id><pub-id pub-id-type="pmid">18254896</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-12-00054"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassler</surname><given-names>S.N.</given-names></name><name><surname>Ahmad</surname><given-names>F.B.</given-names></name><name><surname>Burgos-Vega</surname><given-names>C.C.</given-names></name><name><surname>Boitano</surname><given-names>S.</given-names></name><name><surname>Vagner</surname><given-names>J.</given-names></name><name><surname>Price</surname><given-names>T.J.</given-names></name><name><surname>Dussor</surname><given-names>G.</given-names></name></person-group><article-title>Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice</article-title><source>Cephalalgia</source><year>2018</year><volume>39</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1177/0333102418779548</pub-id><pub-id pub-id-type="pmid">29848111</pub-id></element-citation></ref><ref id="B86-pharmaceuticals-12-00054"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>C.</given-names></name><name><surname>Gupta</surname><given-names>R.</given-names></name><name><surname>Jordt</surname><given-names>S.E.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liedtke</surname><given-names>W.B.</given-names></name></person-group><article-title>Regulation of Pain and Itch by TRP Channels</article-title><source>Neurosci. Bull.</source><year>2018</year><volume>34</volume><fpage>120</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1007/s12264-017-0200-8</pub-id><pub-id pub-id-type="pmid">29282613</pub-id></element-citation></ref><ref id="B87-pharmaceuticals-12-00054"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weyer</surname><given-names>A.D.</given-names></name><name><surname>Lehto</surname><given-names>S.G.</given-names></name></person-group><article-title>Development of TRPM8 Antagonists to Treat Chronic Pain and Migraine</article-title><source>Pharmaceuticals</source><year>2017</year><volume>10</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.3390/ph10020037</pub-id></element-citation></ref><ref id="B88-pharmaceuticals-12-00054"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.P.</given-names></name><name><surname>Fuh</surname><given-names>J.L.</given-names></name><name><surname>Chung</surname><given-names>M.Y.</given-names></name><name><surname>Lin</surname><given-names>Y.C.</given-names></name><name><surname>Liao</surname><given-names>Y.C.</given-names></name><name><surname>Wang</surname><given-names>Y.F.</given-names></name><name><surname>Hsu</surname><given-names>C.L.</given-names></name><name><surname>Yang</surname><given-names>U.C.</given-names></name><name><surname>Lin</surname><given-names>M.W.</given-names></name><name><surname>Chiou</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies novel susceptibility loci for migraine in Han Chinese resided in Taiwan</article-title><source>Cephalalgia</source><year>2018</year><volume>38</volume><fpage>466</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1177/0333102417695105</pub-id><pub-id pub-id-type="pmid">28952330</pub-id></element-citation></ref><ref id="B89-pharmaceuticals-12-00054"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Dhaka</surname><given-names>A.</given-names></name><name><surname>Cao</surname><given-names>Y.Q.</given-names></name></person-group><article-title>Function and postnatal changes of dural afferent fibers expressing TRPM8 channels</article-title><source>Mol. Pain</source><year>2015</year><volume>11</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/s12990-015-0043-0</pub-id><pub-id pub-id-type="pmid">26111800</pub-id></element-citation></ref><ref id="B90-pharmaceuticals-12-00054"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Chang</surname><given-names>M.J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Dhaka</surname><given-names>A.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Cao</surname><given-names>Y.Q.</given-names></name></person-group><article-title>Quantitative Analysis of Mouse Dural Afferent Neurons Expressing TRPM8, VGLUT3, and NF200</article-title><source>Headache</source><year>2018</year><volume>58</volume><fpage>88</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/head.13188</pub-id><pub-id pub-id-type="pmid">28925503</pub-id></element-citation></ref><ref id="B91-pharmaceuticals-12-00054"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgos-Vega</surname><given-names>C.C.</given-names></name><name><surname>Ahn</surname><given-names>D.D.</given-names></name><name><surname>Bischoff</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Horne</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Gavva</surname><given-names>N.</given-names></name><name><surname>Dussor</surname><given-names>G.</given-names></name></person-group><article-title>Meningeal transient receptor potential channel M8 activation causes cutaneous facial and hindpaw allodynia in a preclinical rodent model of headache</article-title><source>Cephalalgia</source><year>2016</year><volume>36</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1177/0333102415584313</pub-id><pub-id pub-id-type="pmid">25944818</pub-id></element-citation></ref><ref id="B92-pharmaceuticals-12-00054"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kayama</surname><given-names>Y.</given-names></name><name><surname>Shibata</surname><given-names>M.</given-names></name><name><surname>Takizawa</surname><given-names>T.</given-names></name><name><surname>Ibata</surname><given-names>K.</given-names></name><name><surname>Shimizu</surname><given-names>T.</given-names></name><name><surname>Ebine</surname><given-names>T.</given-names></name><name><surname>Toriumi</surname><given-names>H.</given-names></name><name><surname>Yuzaki</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>N.</given-names></name></person-group><article-title>Functional interactions between transient receptor potential M8 and transient receptor potential V1 in the trigeminal system: Relevance to migraine pathophysiology</article-title><source>Cephalalgia</source><year>2018</year><volume>38</volume><fpage>833</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1177/0333102417712719</pub-id><pub-id pub-id-type="pmid">28554243</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-12-00054"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Fukuoka</surname><given-names>T.</given-names></name><name><surname>Obata</surname><given-names>K.</given-names></name><name><surname>Yamanaka</surname><given-names>H.</given-names></name><name><surname>Dai</surname><given-names>Y.</given-names></name><name><surname>Tokunaga</surname><given-names>A.</given-names></name><name><surname>Noguchi</surname><given-names>K.</given-names></name></person-group><article-title>Distinct expression of TRPM8, TRPA1, and TRPV1 mRNAs in rat primary afferent neurons with a&#x003b4;/c-fibers and colocalization with trk receptors</article-title><source>J. Comp. Neurol.</source><year>2005</year><volume>493</volume><fpage>596</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1002/cne.20794</pub-id><pub-id pub-id-type="pmid">16304633</pub-id></element-citation></ref><ref id="B94-pharmaceuticals-12-00054"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>J.</given-names></name><name><surname>Hosokawa</surname><given-names>H.</given-names></name><name><surname>Okazawa</surname><given-names>M.</given-names></name><name><surname>Kandachi</surname><given-names>M.</given-names></name><name><surname>Sawada</surname><given-names>Y.</given-names></name><name><surname>Yamanaka</surname><given-names>K.</given-names></name><name><surname>Matsumura</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>S.</given-names></name></person-group><article-title>TRPM8 protein localization in trigeminal ganglion and taste papillae</article-title><source>Brain Res. Mol. Brain Res.</source><year>2005</year><volume>136</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.molbrainres.2005.01.013</pub-id><pub-id pub-id-type="pmid">15893591</pub-id></element-citation></ref><ref id="B95-pharmaceuticals-12-00054"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horne</surname><given-names>D.B.</given-names></name><name><surname>Biswas</surname><given-names>K.</given-names></name><name><surname>Brown</surname><given-names>J.</given-names></name><name><surname>Bartberger</surname><given-names>M.D.</given-names></name><name><surname>Clarine</surname><given-names>J.</given-names></name><name><surname>Davis</surname><given-names>C.D.</given-names></name><name><surname>Gore</surname><given-names>V.K.</given-names></name><name><surname>Harried</surname><given-names>S.</given-names></name><name><surname>Horner</surname><given-names>M.</given-names></name><name><surname>Kaller</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Discovery of TRPM8 Antagonist(S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoy l)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine</article-title><source>J. Med. Chem.</source><year>2018</year><volume>61</volume><fpage>8186</fpage><lpage>8201</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00518</pub-id><pub-id pub-id-type="pmid">30148953</pub-id></element-citation></ref><ref id="B96-pharmaceuticals-12-00054"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Key</surname><given-names>F.M.</given-names></name><name><surname>Abdul-Aziz</surname><given-names>M.A.</given-names></name><name><surname>Mundry</surname><given-names>R.</given-names></name><name><surname>Peter</surname><given-names>B.M.</given-names></name><name><surname>Sekar</surname><given-names>A.</given-names></name><name><surname>D&#x02019;Amato</surname><given-names>M.</given-names></name><name><surname>Dennis</surname><given-names>M.Y.</given-names></name><name><surname>Schmidt</surname><given-names>J.M.</given-names></name><name><surname>Andres</surname><given-names>A.M.</given-names></name></person-group><article-title>Human local adaptation of the TRPM8 cold receptor along a latitudinal cline</article-title><source>PLoS Genet.</source><year>2018</year><volume>14</volume><elocation-id>e1007298</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007298</pub-id><pub-id pub-id-type="pmid">29723195</pub-id></element-citation></ref><ref id="B97-pharmaceuticals-12-00054"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chasman</surname><given-names>D.I.</given-names></name><name><surname>Schurks</surname><given-names>M.</given-names></name><name><surname>Anttila</surname><given-names>V.</given-names></name><name><surname>de Vries</surname><given-names>B.</given-names></name><name><surname>Schminke</surname><given-names>U.</given-names></name><name><surname>Launer</surname><given-names>L.J.</given-names></name><name><surname>Terwindt</surname><given-names>G.M.</given-names></name><name><surname>van den Maagdenberg</surname><given-names>A.M.</given-names></name><name><surname>Fendrich</surname><given-names>K.</given-names></name><name><surname>Volzke</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Genome-wide association study reveals three susceptibility loci for common migraine in the general population</article-title><source>Nat. Genet.</source><year>2011</year><volume>43</volume><fpage>695</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1038/ng.856</pub-id><pub-id pub-id-type="pmid">21666692</pub-id></element-citation></ref><ref id="B98-pharmaceuticals-12-00054"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassini</surname><given-names>R.</given-names></name><name><surname>Materazzi</surname><given-names>S.</given-names></name><name><surname>Benemei</surname><given-names>S.</given-names></name><name><surname>Geppetti</surname><given-names>P.</given-names></name></person-group><article-title>The TRPA1 channel in inflammatory and neuropathic pain and migraine</article-title><source>Rev. Physiol. Biochem. Pharmacol.</source><year>2014</year><volume>167</volume><fpage>1</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">24668446</pub-id></element-citation></ref><ref id="B99-pharmaceuticals-12-00054"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.W.</given-names></name><name><surname>Vernon</surname><given-names>H.</given-names></name><name><surname>Tatourian</surname><given-names>I.</given-names></name></person-group><article-title>Changes in neck electromyography associated with meningeal noxious stimulation</article-title><source>J. Manip. Physiol. Ther.</source><year>1995</year><volume>18</volume><fpage>577</fpage><lpage>581</lpage></element-citation></ref><ref id="B100-pharmaceuticals-12-00054"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaible</surname><given-names>H.G.</given-names></name><name><surname>Ebersberger</surname><given-names>A.</given-names></name><name><surname>Peppel</surname><given-names>P.</given-names></name><name><surname>Beck</surname><given-names>U.</given-names></name><name><surname>Messlinger</surname><given-names>K.</given-names></name></person-group><article-title>Release of immunoreactive substance P in the trigeminal brain stem nuclear complex evoked by chemical stimulation of the nasal mucosa and the dura mater encephali--a study with antibody microprobes</article-title><source>Neuroscience</source><year>1997</year><volume>76</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/S0306-4522(96)00353-3</pub-id><pub-id pub-id-type="pmid">8971777</pub-id></element-citation></ref><ref id="B101-pharmaceuticals-12-00054"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartsch</surname><given-names>T.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name></person-group><article-title>Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater</article-title><source>Brain</source><year>2003</year><volume>126</volume><fpage>1801</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1093/brain/awg190</pub-id><pub-id pub-id-type="pmid">12821523</pub-id></element-citation></ref><ref id="B102-pharmaceuticals-12-00054"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benemei</surname><given-names>S.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name><name><surname>Geppetti</surname><given-names>P.</given-names></name></person-group><article-title>Pleasant natural scent with unpleasant effects: Cluster headache-like attacks triggered by Umbellularia californica</article-title><source>Cephalalgia</source><year>2010</year><volume>30</volume><fpage>744</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2009.01988.x</pub-id><?supplied-pmid 19732077?><pub-id pub-id-type="pmid">19732077</pub-id></element-citation></ref><ref id="B103-pharmaceuticals-12-00054"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassini</surname><given-names>R.</given-names></name><name><surname>Materazzi</surname><given-names>S.</given-names></name><name><surname>Vriens</surname><given-names>J.</given-names></name><name><surname>Prenen</surname><given-names>J.</given-names></name><name><surname>Benemei</surname><given-names>S.</given-names></name><name><surname>De Siena</surname><given-names>G.</given-names></name><name><surname>la Marca</surname><given-names>G.</given-names></name><name><surname>Andre</surname><given-names>E.</given-names></name><name><surname>Preti</surname><given-names>D.</given-names></name><name><surname>Avonto</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The &#x02018;headache tree&#x02019; via umbellulone and TRPA1 activates the trigeminovascular system</article-title><source>Brain J. Neurol.</source><year>2012</year><volume>135</volume><fpage>376</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1093/brain/awr272</pub-id></element-citation></ref><ref id="B104-pharmaceuticals-12-00054"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J.</given-names></name><name><surname>Minassi</surname><given-names>A.</given-names></name><name><surname>Prenen</surname><given-names>J.</given-names></name><name><surname>Taglialatela-Scafati</surname><given-names>O.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name><name><surname>Nilius</surname><given-names>B.</given-names></name></person-group><article-title>Umbellulone modulates TRP channels</article-title><source>Pflug. Arch.</source><year>2011</year><volume>462</volume><fpage>861</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1007/s00424-011-1043-1</pub-id></element-citation></ref><ref id="B105-pharmaceuticals-12-00054"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edelmayer</surname><given-names>R.M.</given-names></name><name><surname>Le</surname><given-names>L.N.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Nassini</surname><given-names>R.</given-names></name><name><surname>Materazzi</surname><given-names>S.</given-names></name><name><surname>Preti</surname><given-names>D.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name><name><surname>Geppetti</surname><given-names>P.</given-names></name><name><surname>Dodick</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Activation of TRPA1 on dural afferents: A potential mechanism of headache pain</article-title><source>Pain</source><year>2012</year><volume>153</volume><fpage>1949</fpage><lpage>1958</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2012.06.012</pub-id><?supplied-pmid 22809691?><pub-id pub-id-type="pmid">22809691</pub-id></element-citation></ref><ref id="B106-pharmaceuticals-12-00054"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>The Transient Receptor Potential Ankyrin Type 1 Plays a Critical Role in Cortical Spreading Depression</article-title><source>Neuroscience</source><year>2018</year><volume>382</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2018.04.025</pub-id><?supplied-pmid 29719223?><pub-id pub-id-type="pmid">29719223</pub-id></element-citation></ref><ref id="B107-pharmaceuticals-12-00054"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Materazzi</surname><given-names>S.</given-names></name><name><surname>Benemei</surname><given-names>S.</given-names></name><name><surname>Fusi</surname><given-names>C.</given-names></name><name><surname>Gualdani</surname><given-names>R.</given-names></name><name><surname>De Siena</surname><given-names>G.</given-names></name><name><surname>Vastani</surname><given-names>N.</given-names></name><name><surname>Andersson</surname><given-names>D.A.</given-names></name><name><surname>Trevisan</surname><given-names>G.</given-names></name><name><surname>Moncelli</surname><given-names>M.R.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel</article-title><source>Pain</source><year>2013</year><volume>154</volume><fpage>2750</fpage><lpage>2758</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2013.08.002</pub-id><pub-id pub-id-type="pmid">23933184</pub-id></element-citation></ref><ref id="B108-pharmaceuticals-12-00054"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benemei</surname><given-names>S.</given-names></name><name><surname>De Logu</surname><given-names>F.</given-names></name><name><surname>Li Puma</surname><given-names>S.</given-names></name><name><surname>Marone</surname><given-names>I.M.</given-names></name><name><surname>Coppi</surname><given-names>E.</given-names></name><name><surname>Ugolini</surname><given-names>F.</given-names></name><name><surname>Liedtke</surname><given-names>W.</given-names></name><name><surname>Pollastro</surname><given-names>F.</given-names></name><name><surname>Appendino</surname><given-names>G.</given-names></name><name><surname>Geppetti</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel</article-title><source>Br. J. Pharmacol.</source><year>2017</year><volume>174</volume><fpage>2897</fpage><lpage>2911</lpage><pub-id pub-id-type="doi">10.1111/bph.13917</pub-id><pub-id pub-id-type="pmid">28622417</pub-id></element-citation></ref><ref id="B109-pharmaceuticals-12-00054"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunkler</surname><given-names>P.E.</given-names></name><name><surname>Ballard</surname><given-names>C.J.</given-names></name><name><surname>Oxford</surname><given-names>G.S.</given-names></name><name><surname>Hurley</surname><given-names>J.H.</given-names></name></person-group><article-title>TRPA1 receptors mediate environmental irritant-induced meningeal vasodilatation</article-title><source>Pain</source><year>2011</year><volume>152</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2010.08.021</pub-id><?supplied-pmid 21075522?><pub-id pub-id-type="pmid">21075522</pub-id></element-citation></ref><ref id="B110-pharmaceuticals-12-00054"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunkler</surname><given-names>P.E.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Pellman</surname><given-names>J.J.</given-names></name><name><surname>Oxford</surname><given-names>G.S.</given-names></name><name><surname>Hurley</surname><given-names>J.H.</given-names></name></person-group><article-title>Sensitization of the trigeminovascular system following environmental irritant exposure</article-title><source>Cephalalgia</source><year>2015</year><pub-id pub-id-type="doi">10.1177/0333102415574845</pub-id></element-citation></ref><ref id="B111-pharmaceuticals-12-00054"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunkler</surname><given-names>P.E.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Johnson</surname><given-names>P.L.</given-names></name><name><surname>Oxford</surname><given-names>G.S.</given-names></name><name><surname>Hurley</surname><given-names>J.H.</given-names></name></person-group><article-title>Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure</article-title><source>Pain</source><year>2018</year><volume>159</volume><fpage>540</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000001124</pub-id><pub-id pub-id-type="pmid">29200178</pub-id></element-citation></ref><ref id="B112-pharmaceuticals-12-00054"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leishman</surname><given-names>E.</given-names></name><name><surname>Kunkler</surname><given-names>P.E.</given-names></name><name><surname>Manchanda</surname><given-names>M.</given-names></name><name><surname>Sangani</surname><given-names>K.</given-names></name><name><surname>Stuart</surname><given-names>J.M.</given-names></name><name><surname>Oxford</surname><given-names>G.S.</given-names></name><name><surname>Hurley</surname><given-names>J.H.</given-names></name><name><surname>Bradshaw</surname><given-names>H.B.</given-names></name></person-group><article-title>Environmental Toxin Acrolein Alters Levels of Endogenous Lipids, Including TRP Agonists: A Potential Mechanism for Headache Driven by TRPA1 Activation</article-title><source>Neurobiol. Pain</source><year>2017</year><volume>1</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.ynpai.2017.03.001</pub-id><pub-id pub-id-type="pmid">29430557</pub-id></element-citation></ref><ref id="B113-pharmaceuticals-12-00054"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberhardt</surname><given-names>M.</given-names></name><name><surname>Dux</surname><given-names>M.</given-names></name><name><surname>Namer</surname><given-names>B.</given-names></name><name><surname>Miljkovic</surname><given-names>J.</given-names></name><name><surname>Cordasic</surname><given-names>N.</given-names></name><name><surname>Will</surname><given-names>C.</given-names></name><name><surname>Kichko</surname><given-names>T.I.</given-names></name><name><surname>de la Roche</surname><given-names>J.</given-names></name><name><surname>Fischer</surname><given-names>M.</given-names></name><name><surname>Suarez</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>4381</fpage><pub-id pub-id-type="doi">10.1038/ncomms5381</pub-id><pub-id pub-id-type="pmid">25023795</pub-id></element-citation></ref><ref id="B114-pharmaceuticals-12-00054"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>V.</given-names></name><name><surname>Messlinger</surname><given-names>K.</given-names></name><name><surname>Fischer</surname><given-names>M.J.</given-names></name></person-group><article-title>Hydrogen sulfide determines HNO-induced stimulation of trigeminal afferents</article-title><source>Neurosci. Lett.</source><year>2015</year><volume>602</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2015.06.056</pub-id><pub-id pub-id-type="pmid">26149232</pub-id></element-citation></ref><ref id="B115-pharmaceuticals-12-00054"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dux</surname><given-names>M.</given-names></name><name><surname>Will</surname><given-names>C.</given-names></name><name><surname>Vogler</surname><given-names>B.</given-names></name><name><surname>Filipovic</surname><given-names>M.R.</given-names></name><name><surname>Messlinger</surname><given-names>K.</given-names></name></person-group><article-title>Meningeal blood flow is controlled by H2 S-NO crosstalk activating a HNO-TRPA1-CGRP signalling pathway</article-title><source>Br. J. Pharmacol.</source><year>2016</year><volume>173</volume><fpage>431</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1111/bph.13164</pub-id><pub-id pub-id-type="pmid">25884403</pub-id></element-citation></ref><ref id="B116-pharmaceuticals-12-00054"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teicher</surname><given-names>C.</given-names></name><name><surname>De Col</surname><given-names>R.</given-names></name><name><surname>Messlinger</surname><given-names>K.</given-names></name></person-group><article-title>Hydrogen Sulfide Mediating both Excitatory and Inhibitory Effects in a Rat Model of Meningeal Nociception and Headache Generation</article-title><source>Front. Neurol.</source><year>2017</year><volume>8</volume><fpage>336</fpage><pub-id pub-id-type="doi">10.3389/fneur.2017.00336</pub-id><pub-id pub-id-type="pmid">28769868</pub-id></element-citation></ref><ref id="B117-pharmaceuticals-12-00054"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denner</surname><given-names>A.C.</given-names></name><name><surname>Vogler</surname><given-names>B.</given-names></name><name><surname>Messlinger</surname><given-names>K.</given-names></name><name><surname>De Col</surname><given-names>R.</given-names></name></person-group><article-title>Role of transient receptor potential ankyrin 1 receptors in rodent models of meningeal nociception&#x02014;Experiments in vitro</article-title><source>Eur. J. Pain</source><year>2017</year><volume>21</volume><fpage>843</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1002/ejp.986</pub-id><pub-id pub-id-type="pmid">27977070</pub-id></element-citation></ref><ref id="B118-pharmaceuticals-12-00054"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J.</given-names></name></person-group><article-title>The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache</article-title><source>Pharmacol. Ther.</source><year>2008</year><volume>120</volume><fpage>157</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.08.003</pub-id><pub-id pub-id-type="pmid">18789357</pub-id></element-citation></ref><ref id="B119-pharmaceuticals-12-00054"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J.</given-names></name></person-group><article-title>Nitric oxide-related drug targets in headache</article-title><source>Neurotherapeutics</source><year>2010</year><volume>7</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.nurt.2010.03.006</pub-id><pub-id pub-id-type="pmid">20430317</pub-id></element-citation></ref><ref id="B120-pharmaceuticals-12-00054"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miclescu</surname><given-names>A.</given-names></name><name><surname>Gordh</surname><given-names>T.</given-names></name></person-group><article-title>Nitric oxide and pain: &#x02018;Something old, something new&#x02019;</article-title><source>Acta Anaesthesiol. Scand.</source><year>2009</year><volume>53</volume><fpage>1107</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.2009.02054.x</pub-id><pub-id pub-id-type="pmid">19702699</pub-id></element-citation></ref><ref id="B121-pharmaceuticals-12-00054"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name></person-group><article-title>The role of nitric oxide in orofacial pain</article-title><source>Nitric Oxide</source><year>2012</year><volume>26</volume><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.niox.2011.11.003</pub-id><pub-id pub-id-type="pmid">22138296</pub-id></element-citation></ref><ref id="B122-pharmaceuticals-12-00054"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tegeder</surname><given-names>I.</given-names></name><name><surname>Scheving</surname><given-names>R.</given-names></name><name><surname>Wittig</surname><given-names>I.</given-names></name><name><surname>Geisslinger</surname><given-names>G.</given-names></name></person-group><article-title>SNO-ing at the nociceptive synapse?</article-title><source>Pharmacol. Rev.</source><year>2011</year><volume>63</volume><fpage>366</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1124/pr.110.004200</pub-id><pub-id pub-id-type="pmid">21436345</pub-id></element-citation></ref><ref id="B123-pharmaceuticals-12-00054"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cury</surname><given-names>Y.</given-names></name><name><surname>Picolo</surname><given-names>G.</given-names></name><name><surname>Gutierrez</surname><given-names>V.P.</given-names></name><name><surname>Ferreira</surname><given-names>S.H.</given-names></name></person-group><article-title>Pain and analgesia: The dual effect of nitric oxide in the nociceptive system</article-title><source>Nitric Oxide</source><year>2011</year><volume>25</volume><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.niox.2011.06.004</pub-id><pub-id pub-id-type="pmid">21723953</pub-id></element-citation></ref><ref id="B124-pharmaceuticals-12-00054"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidtko</surname><given-names>A.</given-names></name><name><surname>Tegeder</surname><given-names>I.</given-names></name><name><surname>Geisslinger</surname><given-names>G.</given-names></name></person-group><article-title>No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing</article-title><source>Trends Neurosci.</source><year>2009</year><volume>32</volume><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2009.01.010</pub-id><pub-id pub-id-type="pmid">19414201</pub-id></element-citation></ref><ref id="B125-pharmaceuticals-12-00054"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollace</surname><given-names>V.</given-names></name><name><surname>Muscoli</surname><given-names>C.</given-names></name><name><surname>Masini</surname><given-names>E.</given-names></name><name><surname>Cuzzocrea</surname><given-names>S.</given-names></name><name><surname>Salvemini</surname><given-names>D.</given-names></name></person-group><article-title>Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors</article-title><source>Pharmacol. Rev.</source><year>2005</year><volume>57</volume><fpage>217</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1124/pr.57.2.1</pub-id><pub-id pub-id-type="pmid">15914468</pub-id></element-citation></ref><ref id="B126-pharmaceuticals-12-00054"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>T.</given-names></name><name><surname>Dubin</surname><given-names>A.E.</given-names></name><name><surname>Petrus</surname><given-names>M.J.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name></person-group><article-title>TRPV1 and TRPA1 mediate peripheral nitric oxide-induced nociception in mice</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e7596</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007596</pub-id><pub-id pub-id-type="pmid">19893614</pub-id></element-citation></ref><ref id="B127-pharmaceuticals-12-00054"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marone</surname><given-names>I.M.</given-names></name><name><surname>De Logu</surname><given-names>F.</given-names></name><name><surname>Nassini</surname><given-names>R.</given-names></name><name><surname>De Carvalho Goncalves</surname><given-names>M.</given-names></name><name><surname>Benemei</surname><given-names>S.</given-names></name><name><surname>Ferreira</surname><given-names>J.</given-names></name><name><surname>Jain</surname><given-names>P.</given-names></name><name><surname>Li Puma</surname><given-names>S.</given-names></name><name><surname>Bunnett</surname><given-names>N.W.</given-names></name><name><surname>Geppetti</surname><given-names>P.</given-names></name><etal/></person-group><article-title>TRPA1/NOX in the soma of trigeminal ganglion neurons mediates migraine-related pain of glyceryl trinitrate in mice</article-title><source>Brain</source><year>2018</year><pub-id pub-id-type="doi">10.1093/brain/awy177</pub-id></element-citation></ref><ref id="B128-pharmaceuticals-12-00054"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demartini</surname><given-names>C.</given-names></name><name><surname>Tassorelli</surname><given-names>C.</given-names></name><name><surname>Zanaboni</surname><given-names>A.M.</given-names></name><name><surname>Tonsi</surname><given-names>G.</given-names></name><name><surname>Francesconi</surname><given-names>O.</given-names></name><name><surname>Nativi</surname><given-names>C.</given-names></name><name><surname>Greco</surname><given-names>R.</given-names></name></person-group><article-title>The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: Evaluation in an animal model</article-title><source>J. Headache Pain</source><year>2017</year><volume>18</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/s10194-017-0804-4</pub-id><pub-id pub-id-type="pmid">28884307</pub-id></element-citation></ref><ref id="B129-pharmaceuticals-12-00054"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lackovic</surname><given-names>Z.</given-names></name><name><surname>Filipovic</surname><given-names>B.</given-names></name><name><surname>Matak</surname><given-names>I.</given-names></name><name><surname>Helyes</surname><given-names>Z.</given-names></name></person-group><article-title>Activity of botulinum toxin type A in cranial dura: Implications for treatment of migraine and other headaches</article-title><source>Br. J. Pharmacol.</source><year>2016</year><volume>173</volume><fpage>279</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1111/bph.13366</pub-id><pub-id pub-id-type="pmid">26493010</pub-id></element-citation></ref><ref id="B130-pharmaceuticals-12-00054"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cernuda-Morollon</surname><given-names>E.</given-names></name><name><surname>Ramon</surname><given-names>C.</given-names></name><name><surname>Martinez-Camblor</surname><given-names>P.</given-names></name><name><surname>Serrano-Pertierra</surname><given-names>E.</given-names></name><name><surname>Larrosa</surname><given-names>D.</given-names></name><name><surname>Pascual</surname><given-names>J.</given-names></name></person-group><article-title>OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine</article-title><source>Pain</source><year>2015</year><volume>156</volume><fpage>820</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000119</pub-id><pub-id pub-id-type="pmid">25735000</pub-id></element-citation></ref><ref id="B131-pharmaceuticals-12-00054"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cady</surname><given-names>R.</given-names></name><name><surname>Turner</surname><given-names>I.</given-names></name><name><surname>Dexter</surname><given-names>K.</given-names></name><name><surname>Beach</surname><given-names>M.E.</given-names></name><name><surname>Cady</surname><given-names>R.</given-names></name><name><surname>Durham</surname><given-names>P.</given-names></name></person-group><article-title>An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine</article-title><source>Headache</source><year>2014</year><volume>54</volume><fpage>269</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1111/head.12250</pub-id><pub-id pub-id-type="pmid">24147647</pub-id></element-citation></ref><ref id="B132-pharmaceuticals-12-00054"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>T.</given-names></name><name><surname>Shibata</surname><given-names>M.</given-names></name><name><surname>Toriumi</surname><given-names>H.</given-names></name><name><surname>Iwashita</surname><given-names>T.</given-names></name><name><surname>Funakubo</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>H.</given-names></name><name><surname>Kuroi</surname><given-names>T.</given-names></name><name><surname>Ebine</surname><given-names>T.</given-names></name><name><surname>Koizumi</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>N.</given-names></name></person-group><article-title>Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A</article-title><source>Neurobiol. Dis.</source><year>2012</year><volume>48</volume><fpage>367</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2012.07.010</pub-id><pub-id pub-id-type="pmid">22820141</pub-id></element-citation></ref><ref id="B133-pharmaceuticals-12-00054"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Steinhoff</surname><given-names>M.</given-names></name><name><surname>Dolly</surname><given-names>J.O.</given-names></name></person-group><article-title>TNFalpha induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>21226</fpage><pub-id pub-id-type="doi">10.1038/srep21226</pub-id><pub-id pub-id-type="pmid">26888187</pub-id></element-citation></ref><ref id="B134-pharmaceuticals-12-00054"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luvisetto</surname><given-names>S.</given-names></name><name><surname>Vacca</surname><given-names>V.</given-names></name><name><surname>Cianchetti</surname><given-names>C.</given-names></name></person-group><article-title>Analgesic effects of botulinum neurotoxin type A in a model of allyl isothiocyanate- and capsaicin-induced pain in mice</article-title><source>Toxicon</source><year>2015</year><volume>94</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2014.12.007</pub-id><pub-id pub-id-type="pmid">25529549</pub-id></element-citation></ref><ref id="B135-pharmaceuticals-12-00054"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Strassman</surname><given-names>A.M.</given-names></name><name><surname>Novack</surname><given-names>V.</given-names></name><name><surname>Brin</surname><given-names>M.F.</given-names></name><name><surname>Burstein</surname><given-names>R.</given-names></name></person-group><article-title>Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors&#x02019; responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?</article-title><source>Cephalalgia</source><year>2016</year><volume>36</volume><fpage>875</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1177/0333102416636843</pub-id><pub-id pub-id-type="pmid">26984967</pub-id></element-citation></ref><ref id="B136-pharmaceuticals-12-00054"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>P.</given-names></name><name><surname>Kuo</surname><given-names>P.H.</given-names></name><name><surname>Lee</surname><given-names>M.T.</given-names></name><name><surname>Chiou</surname><given-names>L.C.</given-names></name><name><surname>Fan</surname><given-names>P.C.</given-names></name></person-group><article-title>Age-Dependent Anti-migraine Effects of Valproic Acid and Topiramate in Rats</article-title><source>Front. Pharmacol.</source><year>2018</year><volume>9</volume><fpage>1095</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.01095</pub-id><pub-id pub-id-type="pmid">30319425</pub-id></element-citation></ref><ref id="B137-pharmaceuticals-12-00054"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashina</surname><given-names>M.</given-names></name><name><surname>Dodick</surname><given-names>D.</given-names></name><name><surname>Goadsby</surname><given-names>P.J.</given-names></name><name><surname>Reuter</surname><given-names>U.</given-names></name><name><surname>Silberstein</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Gage</surname><given-names>J.R.</given-names></name><name><surname>Cheng</surname><given-names>S.</given-names></name><name><surname>Mikol</surname><given-names>D.D.</given-names></name><name><surname>Lenz</surname><given-names>R.A.</given-names></name></person-group><article-title>Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study</article-title><source>Neurology</source><year>2017</year><volume>89</volume><fpage>1237</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004391</pub-id><pub-id pub-id-type="pmid">28835404</pub-id></element-citation></ref><ref id="B138-pharmaceuticals-12-00054"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepper</surname><given-names>S.J.</given-names></name></person-group><article-title>Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018</article-title><source>Headache</source><year>2018</year><volume>58</volume><issue>Suppl. 3</issue><fpage>276</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1111/head.13417</pub-id><pub-id pub-id-type="pmid">30403405</pub-id></element-citation></ref><ref id="B139-pharmaceuticals-12-00054"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>S.</given-names></name><name><surname>Freitag</surname><given-names>F.</given-names></name><name><surname>Phillips</surname><given-names>S.B.</given-names></name><name><surname>Bernstein</surname><given-names>J.E.</given-names></name><name><surname>Saper</surname><given-names>J.R.</given-names></name></person-group><article-title>Intranasal civamide for the acute treatment of migraine headache</article-title><source>Cephalalgia</source><year>2000</year><volume>20</volume><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2000.00088.x</pub-id><pub-id pub-id-type="pmid">11075845</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceuticals-12-00054-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><bold>TRP channels on trigeminal afferents and their potential role in migraine pathology.</bold> Multiple TRP channels are expressed on trigeminal sensory neurons innervating the meninges including TRPV1, TRPA1, TRPV4, and TRPM8. These channels respond to stimuli implicated in migraine, both from a pathology perspective (e.g. acrolein on TRPA1) and a therapeutic perspective (e.g. parthenolide on TRPA1). Additional modulators are listed below their respective TRP channels. Activation of TRP channels on meningeal afferents leads to action potential signaling into the trigeminal nucleus caudalis (left) and ultimately to headache. Activation of TRP channels on these neurons also leads to the release of neuropeptides such as CGRP, activating CGRP receptors on blood vessels (right and bottom), causing vasodilation and contributing to neurogenic inflammation. Although not shown, TRP channels are also expressed on the central terminals of meningeal afferents, and CGRP is released as a transmitter in this synapse, both of which may also contribute to signaling within this circuit. Multiple migraine therapeutics may act in this circuit, including: BoNTA, which may indirectly contribute to decreased CGRP release and possibly inhibit recruitment of TRP channels to the membrane; GEPANTs, which block the CGRP receptor; antiCGRP mAbs, which sequester extracellular CGRP; and antiCGRP-R mAbs, which bind to and block the CGRP receptor. Abbreviations are found in the lower right corner.</p></caption><graphic xlink:href="pharmaceuticals-12-00054-g001"/></fig></floats-group></article>